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DEVELOPMENT OF QUANTITATIVE BIOANALYTICAL METHODS FOR THE
PHARMACOLOGICAL STUDIES OF ANTI-CANCER DRUGS
YE FENG
ABSTRACT
In the anticancer drug discovery and therapy development, it is essential to
understand the pharmacological properties of the drugs. Today, pharmaceutical analysis
is employed throughout the whole drug discovery and development process.
Pharmacokinetic-pharmacodynamic relationships are playing an increasingly important
role in decisions on the rational development and use of new drugs; and they can provide
a detailed knowledge of the mechanism of the drug and a better understanding of the
molecular targets on which they act. Due to the significance of pharmacological analysis,
sensitive analytical methods are critically needed for pharmacological studies. Therefore,
our long-term goal is to provide guidelines in pharmacological studies of the anticancer
drugs by quantitatively evaluating the molecular mechanisms of the drugs.
In this dissertation, the theory behind the analytical processes and modern
bioanalytical technologies, together with their applications in pharmacological studies are
discussed in Chapter 1. Dependent on the type of molecules analyzed, different methods
were developed to achieve the accurate and reliable detection. Specifically, the
development of two HPLC methods with both the UV (Chapter 2) and MS (Chapter 3)
iv

detection for analysis of triapine, a ribonucleotide reductase inhibitor, is presented. In the
UV method, the chelating nature of triapine was investigated by spectrophotometry,
which provides an effective strategy to avoid the unwanted complexation reaction in the
quantitation of triapine. An LC-MS/MS method was successfully applied to
measurements of patients’ samples for pharmacokinetic studies of this drug. Another LCMS/MS method was developed for quantification of fludarabine incorporated in DNA
(Chapter 4). To the best of our knowledge, this is the first LC-MS/MS method developed
for quantification of the amount of fludarabine incorporated. The significance of this
study is that it provides an accurate method to study the fludarabine pharmacological
effect. Moreover, the cytotoxicity mechanism of fludarabine was revisited by developing
an LC-MS/MS method in conjunction with enzymatic digestion (Chapter 5). In this
study, we found that the vast majority of fludarabine was incorporated in the internal
position. The significance of this finding is that it allows physicians to develop better
therapeutic strategies to use this drug for treatment of cancer. Finally, we applied the LCMS/MS method developed in the study of Chapters 4 and 5 to elucidate the action of
fludarabine on RNA metabolism (Chapter 6). In this study, we successfully determined
the quantity of fludarabine incorporated into RNA. In addition, we were able to elucidate
the primary incorporation position of fludarabine in RNA.

v
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CHAPTER I
INTRODUCTION TO PHARMACOLOGICAL STUDY OF DRUGS AND
BIOANALYTICAL METHOD DEVELOPMENT

1.1.

General introduction

1.1.1. Pharmacological studies of anti-cancer drugs
Cancer continues to be one of the major causes of mortality throughout the
world. Common cancer treatment methods include chemotherapy, surgery and
radiotherapy. Since the introduction of using nitrogen mustard for the treatment of
Hodgkin's lymphoma in the late 1940s [1], the use of effective chemotherapeutic agents
has been demonstrated to relieve symptoms and improve survival in patients with various
types of cancer. Over recent years, rapid development of drug discovery technologies and
current insights into molecular targets have increased the availability of potential new
agents through integrative and innovative approaches in drug discovery and hasten the
drug discovery process [2]. Since 1990, 80,000 compounds that NCI’s Developmental
Therapeutics Program (DTP) have, have been screened as potential drug candidates [3].
The key of establishing effective chemotherapy strategies lines in an understanding of the
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pharmacological properties of the drugs [2].
The two major areas of pharmacological study are pharmacokinetics and
pharmacodynamics. Pharmacokinetics (PK) describes how the body affects a specific
drug after administration. PK is divided into several areas including the extent and
rate of liberation, absorption, distribution, metabolism and excretion. This is
commonly referred to as the LADME scheme [4]. Liberation refers to the manner that
the drug is released from specific formulations. Absorption illustrates how the drug is
introduced to the body. Distribution is the dispersion or dissemination of the drug within
the bodily fluids and tissues. Metabolism focuses on the transformation of the original
drug into metabolites. Excretion described how the drug is removed from the body. The
purpose of PK is to study the LADME processes of drugs in the body by examining
the time course of the drug concentration profiles in body fluids such as plasma,
urine and blood. In general, all the drug’s PK parameters including volume of
distribution, half-life, and clearance can be estimated from its concentration vs. time
profiles.
Pharmacodynamics (PD) is the study of the relationships between the
concentrations of a drug at the receptor or target organ (effect sites) and the intensity
of its pharmacological effect. It has a focus of understanding the functioning
mechanisms of the drug and usually involves three major objects: receptor binding, postreceptor effects, and chemical interactions [5]. The major goal of PD study is to
establish the dose-response profile, thus PD study is often carried out together with
the PK study. Generally, there are three different stages to be considered when
studying the overall time course of a dose-effect relationship (see Figure 1.1.) [6]. It
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is crucial to build the PK/PD profiles of new drugs because they can offer 1) a better
understanding of pharmacological behaviors of drugs; 2) an opportunity for
recognizing the presence of active metabolites; 3) a better strategy for a therapeutic
dose regimen; and 4) a better understanding of potential drug-drug interactions.
Overall, pharmaceutical analysis is employed throughout the entire drug
discovery and development process. It is used to provide accurate and precise data,
supporting not only drug discovery and development, but also post-market surveillance
[7]. Pharmacokinetic-pharmacodynamic relationships are playing an increasingly
important role in decisions on the rational development and use of new drugs, and can
provide a detailed knowledge of the mechanism of the drug and a better understanding of
the molecular targets on which they act. Due to the significance of pharmacological
analysis, sensitive analytical methods are critically needed for pharmacological studies.

!
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Figure 1.1, Relationships between the dose and the intensity of pharmacological
effects at the three stages. STAGE1: the relationship between the dose and the time
course of drug concentrations in biological fluids; STAGE2: the time-dependent
relationship between the drug concentrations in biological fluids such as plasma and
the effect site; STAGE3: the relationship between drug concentration at effect site
and the observed pharmacological effects; Cp(t): concentration of drug in biological
fluids such as plasma or blood at time t, Ce(t): concentration of drug at the effect site
at time t.
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1.1.2. Modern analytical technologies
In the past decades, demands on the analytical support for pharmacological
studies have intensified. As a result, new technologies are continually evolving to meet
the demands. Since the first combination of techniques was successfully
accomplished with gas chromatography-MS (GC-MS) in the 1960s [7], many
hyphenated bioanalytical techniques have been successfully developed for the
pharmaceutical analysis. Today, chromatographic based hyphenated techniques are
widely used in pharmacological studies. Chromatography consists of a variety of
techniques, which have the common feature that the components of the sample are
partitioning between a stationary and a mobile phase. Among all of chromatographic
technologies, gas chromatography (GC) and liquid chromatography (LC) are most
commonly utilized in pharmaceutical research.
GC is a type of chromatography for separating and analyzing compounds that
can be vaporized without decomposition. In GC, the mobile phase is a carrier gas,
usually an inert gas such as helium or an unreactive gas such as nitrogen. The
stationary phase can be either solid (adsorption chromatography) or liquid fixed onto a
solid carrier (partition or absorption chromatography). The commonly used detectors in
GC include Thermal Conductivity Detector (TCD), Flame Ionization Detector (FID),
Electron Capture Detector (ECD), Mass Spectrometry (MS) detector and Infrared
Spectrophotometric (IR) detectors. Other special detectors for GC are also available such
as Photoionization Detector (PID), Flame Photometric Detector (FPD), Pulsed Flame
Photometric Detector (PFPD) and Atomic Emission Detector (AED) [8].
The main drawback of GC is that it is only suitable for analysis of volatile and
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thermally stable compounds. This requirement limits the applicability of the GC methods,
i.e., GC cannot analyze thermally labile and high molecular weight molecules such as
biomolecules and polymers. In contrast, LC can be utilized for analysis of such analyte
molecules. LC is a separation technique in which the mobile phase is a liquid. It can
separate an analyte from other interference compounds by introducing the analyte in
a mobile phase to a stationary phase (column) and allowing its interaction to resolve
the constituents. The most commonly used detection methods in LC include UV-VIS
spectroscopy, fluorescence, electrochemical, or MS detectors. Other detectors based on
the

measurement

of

optical

density,

light

scattering,

polarimetry

and

IR

spectrophotometer can also be used with LC. Combined HPLC-NMR spectroscopy is
another rapidly growing technology, enabling the rapid and detailed structural
characterization of the complex mixtures [9]. In general, LC is more widely used than
GC in drug analysis.
When the mobile phase is a supercritical, i.e. a compound above its critical
temperature and pressure, the chromatographic method is called supercritical fluid
chromatography (SFC). SFC’s principles are similar to those of LC, but SFC typically
utilizes carbon dioxide as the mobile phase. Because SFC can be used for the separation
of chiral compounds, it is now commonly used for achiral separations and purifications in
the pharmaceutical industry. However, because several high-pressure pumps are
necessary for SFC, its hardware costs are higher. In addition, SFC may not not highly
reproducible and robust. As a result, the pharmaceutical and quality assurance regulations
limit the usage of SFC in drug analysis [10].
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1.1.3. Quantitative analytical methods and pharmacological studies
Accurate measurements of drug level are essential to the pharmacological study.
Drug level measurements can be used to study the mechanism of drug action, including
the contribution of metabolites to the observed drug effects. Moreover, drug level
measurements can provide insights of how to optimize drug dosage regimens.
Furthermore, bioavailability studies also depend on drug level measurements. Drug level
measurements are achieved by using analytical techniques that are suitable for the
quantitative determination of drugs and their metabolites in biological samples. Several
important factors should be considered when developing a quantitative method for drug
analysis. The first factor is cost. The method developed should be cost-effective. The
second factor is time. The total sample preparation and run time should be short to enable
the high throughput operation. The third factor is simplicity. The very complex procedure
should be avoided as much as possible in the method developed. The fourth factor is
robustness. The method developed should be highly reliable and reproducible.
In my Ph.D study, I focused on the development of quantitative methods that
utilize high performance liquid chromatography for separation in conjunction with
either ultraviolet spectroscopy (HPLC-UV) or tandem mass spectrometry (HPLCMS/MS) for detection to provide accurate and reliable data for pharmacological
studies. A quantitative analytical method generally consists of three steps: biological
sample preparation, HPLC separation, and detection of the analytes of interest. After
method development, the analytical method shall be validated or evaluated for its
performance before it can be used in pharmacological studies. In the remaining of this
chapter, I will discuss each of these topics in details.

!
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1.2.

Biological sample preparation
Quantitative bioanalytical methods should be capable of detecting trace amounts

of analytes in various biological specimens, i.e., plasma, urine, saliva or tissue, which
contain higher contents of proteins, salts, and lipids that may interfere with analysis.
Therefore, extraction of the analytes of interest from a biological specimen prior to
analysis is essential to the successful application of an analytical technique.
Moreover, sample preparation can prevent analytical equipment from contamination
by lipids, proteins, and undissolved particles. Sample cleanup is generally achieved by
protein precipitation (PPT), liquid-liquid extraction (LLE), or solid phase extraction
(SPE).

1.2.1. Protein Precipitation
Protein is one of the matrix molecules present in all biological samples, which
often interfere with analysis. The simplest way to remove protein from a sample is to
precipitate it by adding organic solvents or a combination of organic solvents and ionic
salts to the sample. After mixing, the mixture is centrifuged and the supernatant
containing the analytes is separated from the precipitated protein. The supernatant can be
either injected directly into an analytical system or further concentrated by evaporation
prior to analysis.
The underlying mechanism of protein precipitation is to reduce the hydration
layer around the protein by the addition of new solvents. There are two types of forces
acting upon a protein molecule in an aqueous solution, repulsive electrostatic force and
attractive electrostatic force. Attractive electrostatic forces are due to induced or
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permanent dipoles of protein molecules, while repulsive electrostatic forces result from
the presence of the hydration layers which can prevent the likelihood of aggregation [11].
Addition of miscible organic solvents such as acetonitrile or methanol can displace water
from the protein surface, decreasing the hydration layer around protein. Because
hydration layers become thinner in the presence of other solvents, proteins are more
likely to aggregate by attractive electrostatic forces.
Protein precipitation is the simplest and fastest sample preparation technique,
which can easily be automated. Compared with other techniques, the highest recovery
can be achieved by protein precipitation. The drawback of protein precipitation is that it
cannot effectively remove salts and many other compounds present in the sample, some
of which may still interfere with analysis [12].

1.2.2.

Liquid-Liquid extraction
Liquid-liquid extraction (LLE) is an efficient technique to separate the analyte

molecules from sample matrix molecules. This separation is based on the difference in
the distribution of a molecule in the water-immiscible organic phase and aqueous phase.
Since most of the biological samples are aqueous solution, organic solvents are often
added to extract the analyte molecules from the aqueous phase. The concept “like
dissolves like” works well in LLE. In general, after extraction, more hydrophilic
compounds are in the aqueous phase, while hydrophobic compounds are mainly in
organic solvents. After mixing two immiscible solvents, a compound dissolved in these
two phases can reach to equilibrium, at which the ratio of the concentration of this
compound in two solvents will no longer change.
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KD = Co/Caq

(1.1)

Where KD is the distribution constant, Co is the concentration of the analyte in the organic
phase, and Caq is the concentration of the analyte in the aqueous phase. Unless KD is
extremely large, there may still be a substantial amount of a solute in the aqueous phase
after a single extraction. Consequently, two, three, or even four extractions are carried out
in sequence to extract the solute from the aqueous phase.
Several methods can be used to increase KD. First, changing the organic solvent
used can increase the solubility of the analyte molecules. Extremely hydrophobic analyte
molecules can be extracted more efficiently with non-polar solvents, such as hexane and
carbon tetrachloride, while polar analytes can be extracted more efficiently with polar
solvents, such as chloroform and ethyl acetate [13]. Second, the salting out effect can be
used to decrease the analyte concentration in the aqueous phase. Moreover, if an analyte
molecule can be ionized, its KD may be increased by suppressing its ionization to make it
more soluble in the organic phase.
LLE is more effective than protein precipitation in removing salts from samples.
However, the drawbacks of LLE include the consumption of large amounts of solvent,
the time-consuming extraction process, and the possible emulsion formation [14].

1.2.3. Solid Phase Extraction
Solid phase extraction (SPE) is a widely used chromatographic method to
separate the analytes of interest from sample matrix molecules. In SPE, the analytes
of interest are extracted from its biological matrix by partitioning of the analytes
between a solid phase and a liquid phase, removing salts and many endogenous
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compounds that may interfere with the analysis. SPE is a more efficient separation
process than LLE, and can achieve a higher recovery of analyte by employing a small
column or cartridge. SFE consists of five major steps: 1) selecting the SPE cartridge;
2) conditioning the solid phase matrix; 3) loading the sample; 4) washing the solid
phase matrix while retaining the analytes of interests, and 5) eluting the analytes of
interest from the solid phase matrix (Figure 1.2).
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Figure 1.2, Five steps of SPE: (1) selection of tube, (2) conditioning of tube, (3) addition
of sample, (4) washing and (5) elution
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The selection of an appropriate SPE cartridge depends on the understanding
of the mechanisms of the interaction between the sorbent and analyte of interest. The
most common retention mechanisms in SPE are based on van der Waals forces
(“non-polar interactions”), hydrogen bonding, dipole-dipole forces (“polar”
interactions) and cation-anion interactions (“ionic” interactions). There are three
general extraction mechanisms used in SPE and they are normal phase, reverse phase,
and ion-exchange, respectively [15]. A simplified procedure for the selection of the
cartridge is illustrated in Figure 1.3.
a) Reversed phase SPE involves an analyte of interest, a polar or moderately
polar sample matrix (mobile phase) and a non-polar stationary phase. The
analyte of interest is typically mid- to non- polar. Several SPE materials, such
as the alkyl- or aryl-bonded silicas (C-18, C-8, C-4, ENVI-18, ENVI-8, and
C-Ph) are used in reversed phase extraction.
b) Normal phase SPE involves a polar analyte, a mid- to non-polar matrix (e.g.
acetone, chlorinated solvents and hexane) and a polar stationary phase. Polarfunctionalized bonded silicas (e.g. LC-CN, LC-NH2, and LC-Diol), and polar
adsorption media (LC-Si, LC-Florisil, ENVI-Florisil, and LC-Alumina)
typically are used in normal phase extraction.
c) Ion exchange SPE is used to extract the compounds that can become ions in a
solution. Anionic (negatively charged) compounds can be isolated on an
aliphatic quaternary amine group (LC-SAX or LC-NH) bonded to the silica
surface. Cationic (positively charged) compounds are isolated by using the
silica with aliphatic sulfonic acid groups (LC-SCX or LC-WCX) that are
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bonded to the surface.
Among the three extraction methods, SPE is the most complicated one and its
utility can be limited by its relatively poor reproducibility due to variations in
adsorbent materials used from one batch to another. The advantages of SPE over
other two methods include more effectively depleting the interfering molecules,
reducing the amount of the organic solvent used, and having a relatively high
recovery. Moreover, although it is more expensive, SPE can be readily automated
both off- and on-line, enabling the high throughput operation.
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!
!

Figure 1.3, Illustration of Selection of SPE Cartridge
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1.3.

High performance liquid chromatography

1.3.1. Introduction
As

mentioned

in

the

previous

section,

high

performance

liquid

chromatography (HPLC) has become the most powerful analytical tool used in
pharmaceutical studies. The principle of HPLC is similar to SPE, which is based on
the distribution of the analytes between the liquid mobile phase and a stationary
phase. HPLC separation depends on types of the stationary phase used. Four major
types of liquid chromatography are normal-phase (NP), reverse-phase (RP), ion
exchange, and size-exclusion chromatography. Since reverse-phase chromatography
is the most widely used one in drug analysis, I will focus my discussion on this type of
chromatography in this dissertation. In the remaining of my dissertation, HPLC stands
for reverse-phase HPLC.
The flow diagram of an HPLC system is displayed in Figure 1.4. The principle
components in the HPLC system are mobile phase, pump, sample injector, column and
detector. Pumps move the mobile phase through a degassing unit and then the eluent goes
into a solvent organizer, which controls its composition. Then eluents are mixed in a
mixing chamber. The sample is drawn by the injector and introduced to the column along
with the mobile phase. The components of the sample are separated through the column,
i.e., the compounds that have stronger interactions with the stationary phase move
slower, and tend to stay longer on the column. Finally eluents go to the detectors.
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Figure 1.4, Flow diagram of HPLC setup
(M: mixing chamber; I: injector; D: detector)

!

17!

1.3.2. Column Selection
A good column allows for suitable resolution of the analytes of interest, low
backpressure generation, minimal solvent consumption and short analysis times.
Therefore, selecting a proper column is essential for the LC method development.
There are several factors to consider when selecting a column, which include column
length, particle size, column diameter (internal diameter), pore size, and bonded
phase [17, 18].
1) Column length is typically predicated by the resolution required from a HPLC
system. The longer a column, the higher the resolution power. However as
column length increases, the backpressure increases which can be unpractical for
many HPLC systems. Moreover, longer column results in longer retention time.
Since HPLC is a diffusion-limited technique and that above analyte retention
factor (k) values of ~10, increasing retention will have little or no effect on
resolution because of decreases in efficiency caused by an increase in
longitudinal molecular diffusion. Therefore column is not always the longer
the better. For drug analysis, 50 to 150 mm columns can provide suitable
resolution.
2) Column internal diameter dictates the speed of analysis and affects the
method sensitivity. The larger diameter results in larger extra column volume,
which may decrease efficiency. Usually 2.1-mm i.d. columns are selected to
save solvent and increase sensitivity when we are working with a limited
sample.
3) The particle size of the stationary phase support affects the efficiency of a
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separation and one typically needs high efficiency when trying to separate a
few components in a short time. Smaller particle sizes bring higher efficiency;
however, this is usually at the expense of an increase in system backpressure.
The most widely used particles are 3.0 or 5.0 µm in diameter and provide
very reasonable efficiencies when used with HPLC systems. Sub-2.0-µm
particles, which provide higher resolution and shorter analysis times, are
typically used with ultrahigh-pressure liquid chromatography (UHPLC)
systems, which are capable of dealing with high system backpressures (1000
bar and greater) and can generate very high efficiencies for high resolution or
very fast separations.
4) Pore size describes the average pore diameter of the pores on the surface of
the silica packing material. The smaller the pore size, the larger the surface
area and therefore the greater carbon loading of the column. One should
choose column packing with small pore (60-100Å) when the solute molecular
weight is less than about 5000Da (Note that most of the drug molecules are
smaller than 5000Da). Otherwise, one should use column packing with the
300Å pore size.
5) There are lots of choices of bonded phases, which offer significant differences
in selectivity. When differences in analyte hydrophobicity are large,
hydrophobic stationary phases can be selected. The length of the carbon chain
in hydrophobic stationary phase typically ranges from C4 to C18. As the
carbon chain length increases, the hydrophobicity of the stationary phase also
increases. It is best to initially select a phase in the middle of the hydrophobic
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spectrum (e.g., C8), and then change to a more hydrophobic phase or more
hydrophilic phase depending on initial results and solubility properties of
sample. Modified alkyl phases with more polar functional groups embedded
within the ligand are used when separating analytes with different (polar)
functional groups. Typically, these phases can be used with 100% aqueous
eluent systems and are better at retaining polar analytes. Phenyl-containing
phases interact strongly with analytes containing p electron systems
(aromatic, unsaturated). Amino, diol and silica phases are traditionally used
for the separation of polar analytes in both reversed-phase and normal-phase
modes. Lately they have also found utility in hydrophilic interaction liquid
chromatography (HILIC) mode in which highly organic eluent systems are
used to retain polar analytes using polar stationary phases.

1.3.3. Mobile Phase Selection
Mobile phase is one of the most important components in RP-HPLC. The type
of mobile phase used may have a great impact on separation. It can also promote or
suppress ionization of the analyte molecules. In general, mobile phase consists of a
mixture of water or an aqueous buffer solution and various water-miscible solvents.
Two main features affected by formulation of mobile phase are solvent polarity and
solvent selectivity [19]. The polarity and selectivity can be optimized by changing
the type of organic solvents, percentage of organic solvents, pH, buffers, and other
additives.
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Table 1.1, Properties of common solvents
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Solvents and eluents can be characterized by their elution strength (Table 1.1).
Generally, if the analytes of interest are more polar, the solvent with larger eluent
strength can be selected; while if compounds are more hydrophobic, the solvent with
smaller eluent strength can be utilized.
Increasing the percentage of organic solvents in mobile phase increases the
“elution power” of mobile phase. Scouting gradient method [20] can be used to select
an optimized % of organic phase.
pH in mobile phase is also important to retention. Le Chateliers principle
applies to the equilibrium when adding acidic or basic species to the mobile phase.
The extent of analyte ionization can also vary with pH of the mobile phase (Figure
1.5). The ionized form is more polar -less well retained under the reversed phase
conditions. Non-ionized is less polar -retained longer under the reversed phase
conditions. pH which ranges from pKa -1 to pKa +1 should be avoided to prevent
poor symmetry of peak. Since traditional RP HPLC is silica based, many columns are
pH restricted. At pH < 2.5, the Si-C bond will be cleaved and more -OH groups will
be created; at pH > 7.5, the silica gel backbone becomes soluble and flows out at the
end of column. Therefore at the beginning of method development, the pH range of
the column needs to be highlighted [21].
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Figure 1.5, Acid base equilibrium
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In respect to buffer choice, there are several factors to consider, including
buffer capacity, concentration, solubility, and evaporability (i.e., mass spec
compatibility). When the analyte is relatively polar and hard to be retained on the reverse
phase column, ion-pairing agent can be added to the mobile phase. This ion-pairing agent
often possesses a relative non-polar moiety that has a stronger interaction with the
stationary phase. After the column is fully equilibrated with the mobile phase, the
stationary phase is kinetically coated with the ion-pairing agent. As the ion-pairing agent
is able to interact with the analyte ions, the analyte can also be retained on the column
temporarily.

1.4.

Detection of Analytes
As mentioned in the above section, there is a vast array of detectors that can be

coupled to HPLC. The discussion presented here focuses on the ultraviolet spectroscopy
and mass spectrometer detectors.

1.4.1.

Ultraviolet Spectroscopic Detector
UV can analyze the majority of organic compounds, and almost 70% of

published HPLC analyses were performed with UV detectors [22]. UV detection is
the most useful and most popular detector for HPLC and widely utilized in
pharmacological studies. Many substances absorb light in the UV range. A diagram
of a typical UV detector is shown in Figure 1.6. Light from the deuterium lamp is
collimated by two curved mirrors onto a holographic diffraction grating. The
dispersed light is then focused by means of a curved mirror, onto a plane mirror and
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light of a specific wavelength is selected by appropriately positioning the angle of the
plane mirror. Light of the selected wavelength is then focused by means of a lens
through the flow cell and, consequently, through the column eluent. The exit beam
from the cell is then focused by another lens onto a photo cell which linearly
responses to the intensity of the transmitted light. The method of combining HPLC
with UV is sensitive, economic, and simple. In this project, an analytical HPLC-UV
method is developed for quantification of Triapine.
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Figure 1.6, The UV detector
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1.4.2. Mass spectrometry
Mass spectrometry (MS) is a technique that identifies the molecules based on
their mass to charge (m/z) ratio. Over the past 15 years, MS has led to remarkable
advances in the fields of biomedical and biological research [23]. Currently,
combining MS with chromatographic separation provides some of the most powerful
techniques available for pharmaceutical analysis. Taking advantages of powerful
separation and sensitive detection, LC-MS analysis is powerful for structural
elucidation, accurate quantification, and metabolites prediction in complex biological
matrices.
The basic working procedure of a mass spectrometer includes several steps
(Figure 1.8). First, the sample is vaporized in the ion source. Then, the vaporized
species in the sample are ionized in the gas phase. Afterward, these ions are
separated based on their m/z ratios in the mass analyzer. Finally, the detector can
amplify the signal of the separated ions, and the collection of ion signals composes
the mass spectrum [24].
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Figure 1.7, Flow diagram of mass spectrometry
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Ion sources used depends on the type of the molecules to be ionized. The
most commonly used ionization methods coupled with liquid chromatography are
electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) [25].
ESI is a soft ionization technique, which involves spraying of a solution of the
sample through a highly charged needle (so-called capillary) at atmospheric pressure
(Figure 1.8). The charged droplets are produced in which the positive or negative
ions are solvated with solvent molecules. Heating gas and nebulization gas is applied
to the charged droplets to cause solvent evaporation. These droplets will then be
further desolvated into even smaller droplets, which creates molecules with attached
protons. The protonated and desolvated molecular ions will then be transferred to the
mass analyzer [26].
APCI is another important ionization source because it is capable of ionizing
less polar compounds (Figure 1.9). Unlike ESI, the ionization process of APCI
occurs in gas phase. Without applying high voltage, the APCI capillary enables the
volatile liquid sample to be heated and spayed first, and then a corona discharge
needle with a high voltage generates ions from the aerosol cloud through interaction
of reagent gas and electrons [27].
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Figure 1.8, Schematic diagram of ESI interface
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Figure 1.9, Schematic diagram of APCI interface
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The mechanisms and characteristics of these two different sources are
summarized below:
! ESI (Electrospray ionization)
" Ionization in solution
" Polar compound
! APCI (Atmospheric pressure chemical ionization)
" Ionization in gas phase (corona discharge region)
" Less Polar compound
" Less gentle ionization
Mass analyzers: when ions interact with the applied electric or magnetic
field, the mass analyzer separates the ions according to their mass to charge ratio
(m/z). Typical mass analyzers include quadrupole MS, ion trap MS, and time-offlight (TOF) MS, each of which has its own characteristics and application area. I
only used Q-TRAP (triple quadrupole linear ion trap mass spectrometer) and Q-TOF
(quadrupole–time-of-flight tandem mass spectrometer) for my dissertation research.
Q-TRAP is two distinct types of instruments in one classis: a linear ion trap
system (IT-MS) and a triple quadrupole system (QQQ) (Figure. 1.10).
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Figure 1.10, A schematic of the Q-TRAP instrument. The final quadrupole Q3 can be
operated as either a conventional RF/DC quadrupole mass filter or as a linear ion trap
mass spectrometer.
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QQQ system is a “tandem-in-space” device [28], meaning that each step of an
MS-MS experiment is carried out at a spatially distinct location in the instrument.
QqQ consists of two quadrupole mass filters (Q1 and Q3) in series and a non massresolving quadruple (Q2) in between. For Q1 and Q3, a DC voltage is applied to two
diagonal rods and a radio frequency is applied to the two opposite diagonal rods. A
specific electromagnetic field is formed between the electrodes. This magnetic field
only allows ions with certain m/z to go through the poles and reach the detector. Q2
is not a true quadrupole but a hexapole with RF-only. It is a collision cell that
accommodates collision-induced dissociation (CID). Briefly, Q1 is used to select the
parent or precursor ions. Q2 breaks parent ions into fragments and passes them to
Q3. Q3 allows selected daughter ions to reach to the detector to be detected.IT-MS
instrument is “tandem-in-time” fashion rather than the “tandem-in-space” manner as
discussed above [28]. This means that, once the ions are introduced into the ion trap,
all of the different steps of ion manipulation occur within the same volume, but at
different times. IT-MS first traps the molecular ions with m/z of interest. Then, in the
same trap chamber, the trapped ions are broken down with CID. Finally, IT-MS
exports the fragments to the detector and generates a spectrum of the fragments. The
advantage of IT-MS, relative to QQQ, lies in its high instrument duty cycles and
increased scanning sensitivity.
The Q-trap instrument combines the advantages of a QQQ with those of ITMS within the same platform. The Q3 can be operated as either a conventional
quadrupole mass filter or as a linear ion trap mass spectrometer. The combination of
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highly selective QQQ scans and high sensitivity IT-MS scans on the same instrument
platform provides rapid identification and confirmation of complex compounds.
Q-TOF instrument has very similar configuration with QQQ, with the
replacement of Q3 by TOF (Figure 1.11). TOF is a method of MS in which ions
mass-to-charge ratio is determined via a time measurement. Ions are accelerated by
an electric field. This acceleration causes an ion having the same kinetic energy as
any other ions with the same charge. The higher charge has the higher kinetic energy.
Then these ions fly freely toward the detector. The velocity of the ion depends on the
mass-to-charge ratio. The ion with smaller m/z ratio flies faster. The configuration of
Q-TOF is shown in Figure. 1.11. The instrument consists of three quadrupoles, Q0,
Q1 and Q2, followed by a reflecting TOF mass analyzer with orthogonal injection of
ions. Q1 selected certain parent ions. Q0 and Q2 are not real mass filters. They are
used to focus ions, and Q2 is also a collision cell. The fragments generated by CID
can then be further resolved and analyzed by TOF. Due to its high mass resolution
and the wide m/z analysis range, Q-TOF is often utilized in the unknown compound
identification and analysis of large molecules such as peptides, proteins, and
oligonucleotides [30].
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Figure 1.11, Schematic diagram of Q-TOF
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1.5.

Method Validation
Once an analytical method has been developed, it is necessary to evaluate the

performance of the method. The NTP (National Toxicology Program) guideline and
the FDA (U.S food and Drug Administration) guideline are two most commonly
accepted standards for method validation. According to FDA and NTP, there are
many parameters required for validation to demonstrate the analytical method
developed reliably and reproducibly. These parameters include selectivity, sensitivity,
recovery, matrix factor, calibration curve, accuracy, precision, and stability. These
validation parameters are described below in detail and are summarized in Table 1.2
[30].
Selectivity is the ability of a bioanalytical method to differentiate and
quantify the analyte of interest in the presence of other components in the sample,
including potential metabolites and endogenous matrix components.
Sensitivity (LLOQ, lower limit of quantification) is the lowest concentration
of an analyte in a sample that can be quantitatively determined with an acceptable
precision and accuracy.
Recovery is a measurement of the extraction efficiency of an analytical
process, reported as a percentage of the known amount of an analyte carried through
the sample extraction and processing steps of the method (equation 1.2).
Recovery = (response spiked analyte) / (response extracted analyte) ×100% (1.2)
Matrix factor is an evaluation of the effectiveness of both the extraction
methods and LC methods and a quantitative measure of the matrix effects due to
suppression or enhancement of ionization in a mass spectrometric detector (equation
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1.3).
Matrix factor = (response in matrix extract) / (response in neat solution) ×100% (1.3)
Calibration Curve: the calibrators must be prepared in the same biological
matrix as the real samples. In general, the calibrators should be prepared by spiking the
know amount of analyte into a biological matrix. The range of reliable response is the
range of concentrations over which the response of the detector, in general, is linear.
Accuracy describes how close the mean test results obtained by the method are to
the nominal spiked concentration of the analyte and is determined by replicate analysis of
samples containing known amounts of the analyte (equation 1.5).
%RE = [(measured – norminal)/norminal] x 100% (1.5)
Precision describes how close individual measurements of an analyte are when
the procedure is applied repeatedly to multiple aliquots of a single homogeneous volume
of biological matrix (equation 1.6).
%CV = (Standard deviation/mean) x 100% (1.6)
To evaluate the accuracy and precision of a method, a set of quality control (QC)
samples are needed. These QC samples usually include at least three concentration levels
(low, medium, and high).
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Table 1.2, Validation Parameter Requirements [30]
Parameter or Process
Selectivity
(matrix
interference)

Validation batches
QC samples

QC acceptance criteria
Calibration standard

Standard
criteria
Matrix blank
Recovery
Stability

!

acceptance

Requirement
Review noninterference in at least 6 sources of matrix for non-MS
assays. For MS assays determine MFs in 6 sources if the
nonisotopically labeled
IS is used. If isotopically labeled IS is used, demonstrate that ISnormalizedMF is close to unity.
Analyze at least 3 batches for accuracy and precision. At least 1
validation batch should be made as large as the largest anticipated
sample analysis batch.
Concentration of QC samples should be:
Low QC: About 3 times the LLOQ
Mid QC: Middle of the range (at about the geometric mean of low and
high QC concentration)
High QC: Near the high end of the range, ~70% to 85% of ULOQ
Dilution QC: Sufficient to cover highest anticipated dilution
Intra- and inter-batch precision (%CV) and accuracy (%RE) should be:
QCs prepared at all concentrations greater than LLOQ ≤15%; QC
prepared at LLOQ concentration ≤20%
Include the following calibration standards with each batch:
Minimum of 6 non-zero standards
Matrix blank: Matrix sample without internal standard
Zero standard: Matrix sample with internal standard
Acceptance criteria for calibration standards are:
LLOQ standard ≤20%; All other standards ≤15%
At least 75% of standards should meet above criteria
Interference in matrix blank should be ≤20% of LLOQ response
Extent of recovery of analyte and IS should be consistent, precise, and
reproducible.
Determine recovery at 3 concentration levels.
Perform the following stability experiments:
Stock solution: Minimum of 6 hours at room temperature
Postpreparative (extracted samples/autosampler tray):
Longest time from preparation through sample analysis. Assess against
fresh standards, except for autosampler reinjection reproducibility.
Benchtop: Stability at ambient temperature (or temperature used for
processing of samples) to cover the duration of time taken to extract the
samples (typically ~4-24 hours).
Freeze-thaw: QC samples at minimum of 2 concentrations, 3 cycles,
completely thawed, refrozen at least 12 hours between cycles, at
anticipated temperature of sample storage.
Long-term: Cover longest time from collection to fi nal analysis for any
sample in study.
Analyze 3 aliquots at low and high concentrations with fresh standard
curves and compare against intended (nominal) concentrations. Longterm stability can be completed postvalidation.
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Stability studies provide information about the effect of sample handling and
storage on analysis. The most common stability studies include the following categories:
short-term stability, long-term stability, freeze-thaw stability, post-preparative stability,
and stock solution stability.
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CHAPTER II
DEVELOPMENT OF A LIQUID CHROMATOGRAPHIC METHOD FOR
QUANTITATIVE DETERMINATION OF TRIAPINE, A RIBONUCLEOTIDE
REDUCTASE INHIBITOR, BY SPECTROPHOTOMETRIC STUDY OF TRIAPINE
COMPLEXATION REACTION
!
!

2.1.

Introduction
Triapine

(3-aminopyridine-2-carboxaldehyde

thiosemicarbazone,

or

3-AP)

(Figure 2.1A) is a metal-ion chelator, belonging to a class of compounds known as α-(N)heterocyclic carboxaldehyde thiosemicarbazones (HCTs).

Even though it has been

reported that triapine is useful for treatments of viral or fungal infections [1] and
neurodegenerative diseases [2], most of current studies have been focusing on its antitumor activity due to the effectiveness of this compound on suppressing tumor growth by
inhibiting the activity of ribonucleotide reductase (RR) [3].
RR is an essential enzyme that catalyzes the strictly conserved reduction reaction
of ribonucleotides to deoxyribonucleotides, the precursors of DNA synthesis, and
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regulates the total rate of DNA synthesis so that a constant ratio of DNA to cell mass can
be maintained during cell proliferation and DNA repair [4]. As an iron-ion-dependant
enzyme, human RR consists of two dimers: M1 (large subunit) and M2 or p53R2 (small
subunit) [5], constituting two forms of RR in human cells (i.e., M2-M1 and p53R2-M1).
RR’s activity is based on the association of the two subunits. The M1 subunit contains
the ribonucleotide binding sites and allosteric effector sites. The M2 (or p53R2) subunit
contains a non-heme iron complexed with a tyrosyl free radical, which is essential for its
catalytic activity [6]. It has been reported that tumor cells are more sensitive to the
cytotoxic effect of RR inhibition than normal cells [4]. Therefore, RR is an attractive
target for antineoplastic agents.
By the intrinsic nature of chelator, triapine can coordinate with ferric ions through
the N–N–S tridentate ligand system and form an octahedral complex with 2:1 molar ratio
of triapines to ferric ion [7]. Triapine inhibits RR’s activity by stripping ferric ion which
is needed for stabilizing the iron-tyrosyl radical from the catalytic site of the small
subunit of RR through the formation of triapine-Fe(III) complex [7]. Reduction of
triapine-Fe(III) complex can produce reactive oxygen species (ROS) which can further
quench the tyrosyl radical on the M2 or p53R2 subunit of RR and cause tumor DNA
breakage [8]. Studies showed that triapine as RR inhibitor is 1000-fold more potent than
hydroxyurea (HU) the only therapeutic agent currently used in chemotherapy [3]; can
significantly decrease RR activity in a variety of cancer cell lines including leukemia,
non-small-cell lung cancer, renal cancer and melanoma; and enhances radiation-mediated
cytotoxicity in cervical and colon cancers [3, 9-13]. Recent clinical studies indicated that

!

45!

triapine synergizes with other chemotherapeutic agents, particularly in cervical cancer
and hematological malignancies, and acts as sensitizer radiation therapy [14-16].
Despite of significant potential of triapine for treatment of human diseases, there
are few analytical studies being conducted on this compound. A recent literature search
by SciFinder Scholar revealed no publication available on analytical method development
and validation for this compound.

Although liquid chromatographic assays were

mentioned for the measurement of triapine in clinical studies [17, 18], these assays
suffered from low sensitivity, poor selectivity, and irreproducibility when being repeated.
The major challenge in developing a quantitative assay for measurement of triapine is
stemmed from the chemical nature of triapine. Being a chelator and a weak acid, triapine
has multiple equilibra in aqueous solution, which are affected by various factors
including solution pH, metal ions and other competing chelators, as well as buffer
composition. In this work, a liquid chromatographic assay for quantitative analysis of
triapine has been developed based on the investigation and optimization of the
aforementioned factors.

The assay used 2-[(3-methoxy-2-pyridinyl)methylene]

hydrazinecarbothioamide (Figure 2.1B) as internal standard (IS), Waters Xterra RP18 as
analytical separation column, 18.0% acetonitrile and 82.0% ammonium bicarbonate
buffer [i.e., 10.0 mM NH4HCO3 and 5.00 mM EDTA (v/v) at pH 8.5] as mobile phase,
and 360 nm as the detection wavelength. The assay has a linear calibration range of 3.001.00 x 103 ng mL-1 with interassay precision and accuracy of 2-4% and -3-9%
respectively. It provides a sensitive and reliable method for accurate measurement of
triapine in aqueous solution.
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Figure 2.1, The chemical structures of (A) triapine and (B) NSC 185051, the internal
standard of LC-UV method.
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2.2.

Experimental

2.2.1

Chemicals and solutions
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone or 3-AP) was

kindly provided by Vion Pharmaceuticals (New Haven, CT, USA) and used as the
chemical

standard

for

the

analyte.

2-[(3-methoxy-2-pyridinyl)methylene]

hydrazinecarbothioamide (CAS 51984-14-6 or NSC 185051) was obtained from the
Developmental Therapeutics Program of the National Cancer Institute at the National
Institutes of Health (Bethesda, MD, USA) and used as the internal standard (IS) for
triapine in the LC-UV method. HPLC-grade of acetonitrile and methanol, ferric chloride,
ethylenediaminetetraacetic acid disodium salt (EDTA), monoammonium phosphate,
diammonium phosphate,!ammonium formate, sodium hydroxide, ammonium hydroxide,
carbonic acid, calcium chloride, zinc chloride, cupric sulfate, magnesium chloride, boric
acid,! phosphoric acid and formic acid were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Ammonium bicarbonate was from EMD Chemicals (Darmstadt, Germany).
Deionized water was obtained from a Barnstead Model 7148 Nanopure® ultrapure water
system of the Thermo Scientific (Asheville, NC, USA).

2.2.2

Solutions for spectrophotometric investigation of triapine complexation reaction
Stock solution of triapine (5.00 mM) was prepared by dissolving accurate amount

of triapine powder in an appropriate volume of methanol and kept at −20 °C before use.
Stock solutions of EDTA (100 mM), ferric chloride (2.50 mM), calcium chloride (2.50
mM), zinc chloride (2.50 mM), cupric sulfate (2.50 mM), and magnesium chloride (2.50
mM) were prepared by dissolving accurate amount of each individual compound in
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appropriate volume of deionized water. The stock solution of EDTA was kept at 4 °C,
and the stock solutions of metal ions were prepared freshly before use.
Universal pH buffer solutions having pH values of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and
12 were prepared by mixing 40.0 mM H3BO3, 40.0 mM H3PO4 and 40.0 mM CH3COOH,
then the mixture was titrated to the desired pH with 1 M NaOH. Ammonium formate
solutions (10.0 and 20.0 mM, pH 3.0 and 8.5) were prepared by dissolving accurate
amount of ammonium formate in appropriate volume of deionized water, and the pH
values were adjusted to 3.0 with the concentrated formic acid, and 8.5 with the
concentrated ammonium hydroxide. Ammonium bicarbonate solutions (10.0 and 20.0
mM, pH 8.5) were prepared by dissolving accurate amounts of ammonium bicarbonate in
deionized water, and the pH was adjusted to 8.5 with the concentrated ammonium
hydroxide. Phosphate buffers (10.0 and 20.0 mM, pH 8.5) were prepared by dissolving
accurate amounts of monoammonium phosphate monohydrate and diammonium
phosphate heptahydrate in appropriate volume of deionized water.
For the study of pH effect on the UV-visible absorption spectra of triapine, eleven
solutions of triapine at the concentration of 100 µM with pH values of 2, 3, 4, 5, 6, 7, 8,
9, 10, 11 and 12 were prepared by dilution of 80.0 µL of 5.00 mM triapine stock solution
with 3920 µL of the universal pH buffer at each specified pH values.
For the study of EDTA effect on the UV-visible absorption spectra of triapineFe(III) complex, six solutions were prepared as follows: (i) mixing 80.0 µL of 5.00 mM
triapine stock solution with 3920 µL of 10.0 mM ammonium formate solution at pH 8.5
[i.e., 100 µM triapine alone]; (ii) mixing 80.0 µL of 5.00 mM triapine stock solution and
80.0 µL of 2.50 mM ferric chloride stock solution with 3840 µL of 10.0 mM ammonium
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formate solution at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Fe(III)]; (iii) mixing 80.0
µL of 5.00 mM triapine stock solution and 80.0 µL of 100 mM EDTA stock solution with
3840 µL of 10.0 mM ammonium formate solution at pH 8.5 (i.e., 100 µM triapine with
2.00 mM EDTA); (iv) mixing 80.0 µL of 2.50 mM ferric chloride stock solution and 80.0
µL of 100 mM EDTA stock solution with 3840 µL of 10.0 mM ammonium formate
solution at pH 8.5 [i.e., 50.0 µM Fe(III) with 2.00 mM EDTA]; (v) mixing 80.0 µL of
5.00 mM triapine stock solution and 80.0 µL of 100 mM EDTA stock solution first, then
80.0 µL of 2.50 mM ferric chloride stock solution with 3760 µL of 10.0 mM ammonium
formate solution at pH 8.5 [i.e., 100 µM triapine with 2.00 mM EDTA and 50.0 µM
Fe(III)]; and (vi) mixing 80.0 µL of 5.00 mM triapine stock solution and 80.0 µL of 2.50
mM ferric chloride stock solution first, then 80.0 µL of 100 mM EDTA stock solution
with 3760 µL of 10.0 mM ammonium formate solution at pH 8.5 [i.e., 100 µM triapine
with 50.0 µM Fe(III) and 2.00 mM EDTA]. The solution vi was prepared in triplicate to
study the effect of EDTA on triapine-Fe(III) complex at temperatures of 22, 37 and 90
°C.
Other metal ions such as Mg(II), Ca(II), Zn(II) and Cu(II) were also tested,
because similar with Fe(III) these metal ions commonly exist in the human body, water
source and the instrument, which can be easily introduced during the experiment. For the
study of the effect of other metal ions on the UV-visible absorption spectra of triapine,
twelve triapine solutions at 100 µM were prepared as follows: (i) mixing 80.0 µL of 5.00
mM triapine stock solution and 80.0 µL of 2.50 mM magnesium chloride stock solution
with 3840 µL of 10.0 mM ammonium formate solution at pH 8.5 [i.e., 100 µM triapine
with 50.0 µM Mg(II)]; (ii) mixing 80.0 µL of 5.00 mM triapine stock solution and 80.0
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µL of 2.50 mM calcium chloride stock solution with 3840 µL of 10.0 mM ammonium
formate solution at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Ca(II)]; (iii) mixing 80.0
µL of 5.00 mM triapine stock solution and 80.0 µL of 2.50 mM zinc chloride stock
solution with 3840 µL of 10.0 mM ammonium formate solution at pH 8.5 [i.e., 100 µM
triapine with 50.0 µM Zn(II)]; (iv) mixing 80.0 µL of 5.00 mM triapine stock solution
and 80.0 µL of 2.50 mM cupric sulfate stock solution with 3840 µL of 10.0 mM
ammonium formate solution at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Cu(II)]; (v)
mixing 80.0 µL of 5.00 mM triapine stock solution, 80.0 µL of 100 mM EDTA stock
solution and 80.0 µL of 2.50 mM magnesium chloride stock solution with 3760 µL of
10.0 mM ammonium formate solution at pH 8.5 [i.e., 100 µM triapine with 2.00 mM
EDTA and 50.0 µM Mg(II)]; (vi) mixing 80.0 µL of 5.00 mM triapine stock solution,
80.0 µL of 100 mM EDTA stock solution and 80.0 µL of 2.50 mM calcium chloride
stock solution with 3760 µL of 10.0 mM ammonium formate solution at pH 8.5 [i.e., 100
µM triapine with 2.00 mM EDTA and 50.0 µM Ca(II)]; (vii) mixing 80.0 µL of 5.00 mM
triapine stock solution, 80.0 µL of 100 mM EDTA stock solution and 80.0 µL of 2.50
mM zinc chloride stock solution with 3760 µL of 10.0 mM ammonium formate solution
at pH 8.5 [i.e., 100 µM triapine with 2.00 mM EDTA and 50.0 µM Zn(II)]; (viii) mixing
80.0 µL of 5.00 mM triapine stock solution, 80.0 µL of 100 mM EDTA stock solution
and 80.0 µL of 2.50 mM cupric sulfate stock solution with 3760 µL of 10.0 mM
ammonium formate solution at pH 8.5 [i.e., 100 µM triapine with 2.00 mM EDTA and
50.0 µM Cu(II)]; the mixtures of triapine, EDTA and metal ions were prepared by two
ways: a) mixing triapine and EDTA first before adding metal ion; b) mixing triapine and
metal ion first before adding EDTA; (ix) mixing 80.0 µL of 5.00 mM triapine stock
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solution with 80.0 µL of 20.0 mM ammonium bicarbonate at pH 8.5 first, then 80.0 µL of
2.50 mM cupric sulfate stock solution with 3760 µL of 10.0 mM ammonium bicarbonate
at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Cu(II) in 10.0 ammonium bicarbonate at
pH 8.5]; (x) mixing 80.0 µL of 5.00 mM triapine stock solution with 80.0 µL of 20.0 mM
ammonium bicarbonate at pH 8.5 first, then 80.0 µL of 2.50 mM zinc chloride stock
solution with 3760 µL of 10.0 mM ammonium bicarbonate at pH 8.5 [i.e., 100 µM
triapine with 50.0 µM Zn(II) in 10.0 mM ammonium bicarbonate at pH 8.5]; (xi) mixing
80.0 µL of 5.00 mM triapine stock solution with 80.0 µL of 20.0 mM phosphate buffer at
pH 8.5 first, then 80.0 µL of 2.50 mM cupric sulfate with 3760 µL of 10.0 mM phosphate
buffer at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Cu(II) in 10.0 mM phosphate buffer
at pH 8.5]; and (xii) mixing 80.0 µL of 5.00 mM triapine stock solution with 80.0 µL of
20.0 mM phosphate buffer at pH 8.5 first, then 80.0 µL of 2.50 mM zinc chloride with
3760 µL of 10.0 mM phosphate buffer at pH 8.5 [i.e., 100 µM triapine with 50.0 µM
Zn(II) in 10.0 mM phosphate buffer at pH 8.5].
For the study of buffer composition on the UV-visible absorption spectra of
triapine-Fe(III) complex, six triapine solutions at 100 µM were prepared as follows: (i)
mixing 80.0 µL of 5.00 mM triapine stock solution and 80.0 µL of 20.0 mM ammonium
formate solution at pH 8.5 first, then 80.0 µL of 2.50 mM ferric chloride stock solution
with 3760 µL of 10.0 mM ammonium formate solution at pH 8.5 [i.e., 100 µM triapine
with 50.0 µM Fe(III) in 10.0 mM ammonium formate at pH 8.5]; (ii) mixing 80.0 µL of
5.00 mM triapine stock solution and 80.0 µL of 20.0 mM ammonium formate solution at
pH 3.0 first, then 80.0 µL of 2.50 mM ferric chloride stock solution with 3760 µL of 10.0
mM ammonium formate solution at pH 3.0 [i.e., 100 µM triapine with 50.0 µM Fe(III) in
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10.0 mM ammonium formate at pH 3.0]; (iii) mixing 80.0 µL of 5.00 mM triapine stock
solution and 80.0 µL of 20.0 mM ammonium bicarbonate solution at pH 8.5 first, then
80.0 µL of 2.50 mM ferric chloride stock solution with 3760 µL of 10.0 mM ammonium
bicarbonate solution at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Fe(III) in 10.0 mM
ammonium bicarbonate at pH 8.5]; (iv) mixing 80.0 µL of 5.00 mM triapine stock
solution and 80.0 µL of 20.0 mM phosphate buffer at pH 8.5 first, then 80.0 µL of 2.50
mM ferric chloride stock solution with 3760 µL of 10.0 mM phosphate buffer at pH 8.5
[i.e., 100 µM triapine with 50.0 µM Fe(III) in 10.0 mM phosphate buffer at pH 8.5]; (v)
mixing 80.0 µL of 5.00 mM triapine stock solution and 80.0 µL of deionized water first,
then 80.0 µL of 2.50 mM ferric chloride stock solution with 3760 µL of deionized water
[i.e., 100 µM triapine with 50.0 µM Fe(III) in water]; and (vi) mixing 80.0 µL of 5.00
mM triapine stock solution, 80.0 µL of deionized water, and 80.0 µL of 2.50 mM ferric
chloride stock solution first, then diluted with 3760 µL of 10.0 mM ammonium
bicarbonate at pH 8.5 [i.e., 100 µM triapine with 50.0 µM Fe(III) in 10.0 mM ammonium
bicarbonate at pH 8.5]. The solution vi was prepared in triplicate to study the effect of
ammonium bicarbonate on triapine-Fe(III) complex under temperatures of 22, 37 and 90
°C.

2.2.3

Solutions for liquid chromatography with ultraviolet detection of triapine
Triapine and the IS stock solutions (1.00 mg mL-1) were prepared by dissolving

0.00100 g of each chemical in 1.00 mL of methanol, separately. Each stock solution was
aliquoted into 1.50 ml amber glass vials at 100 µL/vial, and kept at −20 °C before use.
Working solution of triapine standard (10.0 µg mL-1) and working solution of the IS
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(10.0 µg mL-1) were freshly prepared by serial dilution of each stock solution with a
mobile phase being tested.
Three mobile phase compositions were tested for chromatographic separation
triapine and the IS. They were as follows: (i) 30% methanol and 70% ammonium
bicarbonate (10.0 mM, pH 8.5) (v/v); (ii) 18% acetonitrile and 82% ammonium
bicarbonate (10.0 mM, pH 8.5) (v/v); and (iii) 18% acetonitrile and 82% ammonium
bicarbonate-EDTA buffer (containing 5.00 mM EDTA and 10.0 mM NH4HCO3, pH 8.5)
(v/v). The mobile phase composition (iii) was chosen as the mobile phase for the
optimized LC-UV method. We had explained the reasons in 3.2.2. Mobile-phase
composition.
Triapine standard solutions (6.00, 18.0, 20.0, 60.0, 180, 200, 600, 1.80 x 103 and
2.00 x 103 ng mL-1) and the IS standard solution (200 ng mL-1) were prepared by serial
dilution of the working solution of triapine (10.0 µg mL-1) and the working solution of
IS (10.0 µg mL-1) with a mobile phase, separately. Triapine calibrators (3.00, 10.0, 30.0,
100, 300, and 1.00 x 103 ng mL-1 of triapine and 100 ng mL-1 of the IS) were prepared
by mixing 500 µL of a triapine standard solution at twice of a calibrator’s concentration
and 500 µL of the IS solution. Triapine quality controls (QCs) (3.00, 9.00, 90.0 and 900
ng mL-1 of triapine and 100 ng mL-1 of the IS) were prepared by mixing 500 µL of a
triapine standard solution at twice of a QC’s concentration and 500 µL of the IS solution.

2.2.4

Instrumentation
Spectrophotometric studies of triapine complexation reaction were performed on

an Agilent 8453E UV-Visible Spectrophotometer (Agilent, Santa Clara, CA, USA) using
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a 10 mm standard quartz cell, which was controlled by the Agilent UV-Visible
ChemStation software. The pH measurements were carried out using a Fisher Scientific
Accument® Basic AB15 pH meter (Fisher Scientific, Pittsburgh, PA, USA), which was
calibrated using pH calibration buffers of 4.0 and 7.0 or 7.0 and 10.0 from EMD
Chemicals (Gibbstown, NJ, USA) depending on the range of pH measurements.
Chemicals were weighted by Ohaus Galaxy® 160D analytical balance with the range of
30 g x 0.01 mg (Parsippany, NJ, USA).
The liquid chromatographic system used in this work consisted of a Shimadzu
LC-10ADVP binary pump (Shimadzu, Columbia, MD, USA), a Shimadzu SIL-10ADVP
autosampler, an inline filter (0.5 µm pore) (Upchurch Scientific, Oak Harbor, WA, USA),
an analytical separation column, and a Shimadzu SPD-10AVVP UV detector. The system
used Shimadzu Class-VP software (version 5.0) for program execution, data acquisition
and processing.

2.2.5

LC-UV method
Chromatographic separation of triapine and the IS was performed at ambient

temperature on a Waters Xterra RP18 (5 µm, 2.1 x 150 mm) column (Waters, Milford,
MA, USA) with a mobile phase containing 18% acetonitrile and 82% ammonium
bicarbonate-EDTA buffer (10.0 mM ammonium bicarbonate and 5.00 mM EDTA at pH
8.5) (v/v) at a flow rate of 0.200 mL/min. The analytes were detected by the UV detector
at wavelength of 360 nm. Prior to initial sample analysis, the analytical column was
equilibrated with the mobile phase for at least 30 min. This method had a sample
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injection volume of 20.0 µL, and a total run time of 8.5 min per sample with the retention
times of 4.7 and 6.4 min for triapine and the IS, respectively.

2.2.6

Stability Studies
The stability of triapine solutions was investigated with low and high QC samples

(i.e., 9.00 and 900 ng mL-1). The studies included QC samples that were kept at 22 and
90 °C for 4, 8, and 24 h, QC samples that undergone three freeze-and-thaw cycles where
the samples were frozen at −20 °C for at least 24 h and thawed at room temperature, and
QC samples that were stored at -20 °C for 30 days prior to analyses, respectively. All the
above experiments were run in triplicate, and the results were compared with freshly
prepared QC samples.

2.3.

Results and discussion

2.3.1. Understanding of factors that affect the spectrophotometric detection of triapine
Several key factors that affect the chemical equilibria of triapine in solution could
affect the spectrophotometric detection of triapine, which include solution pH, metal ions,
and other chelators, as well as buffer composition. In this work, the effects of these
factors had been investigated.

2.3.1.1. Effect of pH on UV-visible absorption spectra of triapine
Triapine has two acidic hydrogen atoms in aqueous solution (Figure 2.2A), whose
pKa values are 4.3 (pKa1) and 10.9 (pKa2), respectively [19]. Previous studies indicated
that pKa1 is attributed to the deprotonation of the pyridinium unit, whereas pKa2 is due to
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the deprotonation of the hydrazinic N–H group of the thiosemicarbazide moiety [20].
The protonated/deprotonated forms of triapine (H2L+, HL, and L-) are determined by
solution pH, which may affect the UV-visible absorption spectra of triapine.
Figure 2.3 showed the mean absorption spectra of triapine as grouped by their
similarity under different solution pHs.

As seen in Figure 2.3, there were three

characteristic spectra which corresponded to three forms of triapine (H2L+, HL, and L-)
under three pH ranges (i.e., pH 2-4, 6-10, and 11-12). When pH was low (< pKa1), H2L+
was the predominant form which yielded a mean λmax at 393 nm (Figure. 2.3A); as pH
increased (> pKa1 and < pKa2), a blue shift of spectrum with a mean λmax at 357 nm was
observed (Figure 2.3B), which was associated with the dissociation of the first H+ from
H2L+ and the production of the neutral form (HL) of triapine; as pH further increased (>
pKa2), the dissociation of the second H+, and the formation of L- form of triapine took
place, which resulted in a red shift with a mean λmax at 367 nm (Figure 2.3C). A solution
pH of 8.5 was chosen for the subsequent study and LC-UV method development. Under
this pH, HL was the predominant form of triapine, which had a λmax at 360 nm (Figure
2.3D).
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Figure 2.2, Chemical equilibria of triapine in aqueous solution and triapine-metal ion complexation reaction
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Figure 2.3, Effect of pH on UV-visible absorption spectra of triapine. (A) pH 2-4; (B)
pH 6-10; (C) pH 11- 12; (D) pH 8.5. [triapine] = 100 µM in the universal pH buffer, and
temperature = 22 °C,
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2.3.1.2. Effect of metal ions on UV-visible absorption spectra of triapine
As discussed in the introduction section, triapine is a metal-ion chelator which
inhibits RR activity by coordinating with Fe(III) ion in the enzyme M2 (or p53R2)
subunit through its N-N-S tridentate ligand and forming octahedral complex with molar
ratio of 2:1 triapine to ferric ion [7]. Triapine can also coordinate with other metal ions
and result in both mono- and bis-ligand complexes [20. 21]. Due to its high stability, the
bis-ligand complex is a more favorable complex in aqueous solution, which is illustrated
in Figure 2.2B.
Figure 2.4 showed the absorption spectra of triapine and triapine-metal ion
mixtures. In comparison to triapine alone (Figure 2.4A), a red shift of λmax (360 nm →
425 nm) with lower absorptive intensity was observed upon the addition of Fe(III) to
triapine solution (Figure 2.4B), which was the result of triapine-Fe(III) complex
formation. Our experiments revealed that the formation of triapine-Fe(III) complex was
not affected by the solution pH (data not shown). Further experiments also indicated that
some metal ions such as Mg(II) and Ca(II) did not affect the absorption spectra of
triapine (Figure 2.4 C and D) due to no complex formation (which was confirmed by
liquid chromatographic experiments – data not shown); whereas the others metal ions
such as Cu(II) and Zn(II) did form complexes with triapine and caused red shifts of λmax
(Figure 2.4E and F). Therefore, the preservation of triapine in its un-complex state is the
key for successful quantitation of this compound.
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Figure 2.4, Effect of metal ions on UV-visible absorption spectra of triapine. (A) triapine
alone; (B) mixture of triapine and Fe(III); (C) mixture of triapine and Mg(II); (D) mixture
of triapine and Ca(II); (E) mixture of triapine and Cu(II); and (F) mixture of triapine and
Zn(II). The above solutions were prepared in 10.0 mM ammonium formate at pH 8.5.
Wherever were applicable [triapine] = 100 µM, [metal ion] = 50 µM, and temperature =
22 °C.3
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2.3.1.3. Effect of EDTA on UV-visible absorption spectra of triapine
To preserve triapine from complexation with metal ions in solution, EDTA as a
competing chelator for metal ions in solution was examined (Figure 2.5).

The

experimental results showed that when EDTA was added into a triapine solution, it did
not change the absorption spectrum of triapine (Figure 2.5A). EDTA and metal ion [i.e.,
Fe(III), Mg(II), Ca(II), Cu(II), or Zn(II)] complexes showed no absorptivity within the
wavelength range in which triapine and its metal complexes peaked out (Figure 2.5B). If
triapine was mixed with EDTA prior to metal ions [i.e., Fe(III), Cu(II), or Zn(II)], no
triapine-metal ion complexes were formed due to the masking effect of EDTA on metal
ions (Figure 2.5C, D and E); however, if triapine was mixed with metal ions prior to
EDTA, some metal ions such as Fe(III) formed complexes with triapine and caused a red
shift of λmax from 360 nm to 425 nm (Figure 2.5F), while other ions such as Cu(II) and
Zn(II) did not (Figure 2.5D and E). Once triapine-Fe(III) complex was formed, heating
the complex in EDTA solution at 37 °C for 2 h would not release triapine from the
complex (Figure 2.5G), and thus a much higher temperature of 90 °C was needed (Figure
2.5H).
In summary, the above experiments reveal that metal ions preferably bind to
EDTA if both EDTA and triapine are present; triapine forms much more stable complex
with Fe(III) than with the other metal ions studied; and preservation of triapine in its
uncomplex state can be achieved by adding EDTA to triapine solution prior to its reaction
with metal ions.
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Figure 2.5. Effect of EDTA on UV-visible absorption spectra of triapine-metal ion
complex. (A) mixture of triapine and EDTA; (B) mixture of EDTA and metal ion [i.e.,
Fe(III), or Mg(II), or, Ca(II), or Cu(II), or Zn(II)]; (C) mixture of triapine, EDTA and
Fe(III) [sequence-specific mixing, i.e., mixed triapine and EDTA first, then added
Fe(III)]; (D) mixture of triapine, EDTA and Cu(II) (sequence-non-specific mixing); (E)
mixture of triapine, EDTA and Zn(II) (sequence-non-specific mixing); (F) mixture of

!

63!

triapine, Fe(III) and EDTA [sequence-specific mixing, i.e., mixed triapine and Fe(III)
first, then added EDTA]; (G) repeated (F), heated at 37 °C for 2 hrs; and (H) repeated (F),
heated at 90 °C for 2 hrs.

The above solutions were prepared in 10.0 mM ammonium

formate at pH 8.5. Wherever were applicable [triapine] = 100 µM, [EDTA] = 2.00 mM,
[metal ion] = 50 µM, and temperature = 22 °C unless otherwise specified.
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2.3.1.4. Effect of buffer composition on UV-visible absorption spectra of triapine-metal
ion complex
Buffer was used to maintain a solution pH at a relatively constant and
predetermined value.

However, buffer composition might affect the complexation

reaction of triapine and metal ions. Hence, it was investigated in this work.
As shown in Figure 2.6, the UV-visible absorption spectra of triapine and Fe(III)
mixtures in 10.0 mM ammonium formate at pH 3.0 and 8.5 (Figure 2.6A and B) showed
no significant difference with the spectrum of triapine-Fe(III) complex in water (Figure
2.6C), which implied that not only ammonium formate buffer did not affect the
complexation reaction of triapine and Fe(III), but also the triapine complexation reaction
was not pH-dependent. However, when triapine and Fe(III) were mixed in 10.0 mM
ammonium bicarbonate or 10.0 mM ammonium phosphate at pH 8.5, the UV-visible
spectra of the mixtures (Figure 2.6D and E) showed no difference with the spectrum of
uncomplexed triapine (Figure 2.4A), which were probably due to the precipitation of
Fe(III) as Fe(OH)3 and FePO4 in the buffer solutions by the following reactions:

Fe 3+ (aq ) + 3HCO3− (aq ) → Fe( HCO3 ) 3 (aq ) → Fe(OH ) 3 ( s) + 3CO2 ( g )

(1)

Fe 3+ (aq ) + PO43− (aq ) → FePO4 ( s)

(2)

!
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Figure 2.6, Effect of buffer composition on UV-visible absorption spectra of triapineFe(III) complex. (A) mixture of triapine and Fe(III) in 10.0 mM ammonium formate at
pH 3.0; (B) mixture of triapine and Fe(III) in 10.0 mM ammonium formate at pH 8.5; and
(C) mixture of triapine and Fe(III) in deionized water; (D) mixture of triapine and Fe(III)
in 10.0 mM ammonium bicarbonate at pH 8.5; (E) mixture of triapine and Fe(III) in 10.0
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mM phosphate buffer at pH 8.5; (F) mixture of triapine and Fe(III) in deionized water,
then diluted with 10.0 mM ammonium bicarbonate at pH 8.5, heated at 37 °C for 2 hrs;
(G) repeated (F), heated at 90 °C for 2 hrs. Wherever were applicable [triapine] = 100
µM, [Fe(III)] = 50 µM, and temperature = 22 °C unless otherwise specified.
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Further experiments showed that once triapine-Fe(III) complex was formed,
neither the bicarbonate buffer nor the phosphate buffer (data not shown) could release
triapine from the complex, no matter it was at 37 °C 2 h (Figure 2.6F) or 90 °C for 2 h
(Figure 2.6G).
Unlike Fe(III), other metal ions such as Zn(II) and Cu(II) could form complexes
with triapine in both ammonium bicarbonate and ammonium phosphate buffers (data not
shown). This was probably due to the presence of ammonia an auxiliary complexing
agent in the buffer solutions, which formed Zn(NH3)2+, Zn(NH3)22+, Zn(NH3)32+ and
Zn(NH3)42+, and Cu(NH3)2+, Cu(NH3)22+, Cu(NH3)32+ and Cu(NH3)42+ complexes in the
solutions and made them available in solution for the complexation reaction with triapine.
The above experiments indicated that ammonium bicarbonate and ammonium
phosphate could prevent the formation of triapine-Fe(III) complex, but they failed to
prevent the formation of triapine-Zn(II) and triapine-Cu(II) complexes. Therefore, the
best way to preserve triapine in its uncomplexed state is to use EDTA solution or EDTA
with ammonium bicarbonate buffer.

2.3.2. LC-UV assay development and optimization
The understandings of chemical properties of triapine and the IS, and key factors
that affect spectrophotometric detection of triapine were applied to the LC-UV method
development and optimization.
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2.3.2.1. Selection of column
Since the logP values of triapine and the IS are 0.983, and 0.937, respectively,
these compounds are rather hydrophobic than hydrophilic; therefore, reverse-phase LC
columns were considered for this work. Separation of triapine and the IS was initially
tested on Phenomenex Gemini C18 (2.0 mm × 50 mm, 5µm particle size), Waters XTerra RPC 18 (2.1 mm x 150 mm, 5 µm particle size), Waters YMC ODS-AQ (2.0 mm ×
50 mm, 5 µm particle size), Waters X-Bridge AQ (2.0 mm × 50 mm, 5µm particle size),
and Waters X-Bridge Phenyl (2.0 mm × 50 mm, 5 µm particle size) columns with a
mobile-phase flow rate of 0.200 mL min-1 and a UV detector set at wavelength of 360
nm. Although reasonable retention time and sufficient resolution were obtained on all
columns tested, Waters X-Terra RPC 18 column was chosen for the method development
because it yielded greater signal response and better peak shape to the analytes.

2.3.2.2. Mobile-phase composition
By the considerations of the retention mechanism of reverse-phase column,
detectable wavelengths of deuterium lamp (190-370 nm) used in a UV detector, chemical
equilibra of triapine in aqueous solution, and minimum pH for effective EDTA
complexation with various metal ions [22], ammonium bicarbonate buffer at pH 8.5 was
chosen for the LC-UV method development.

In this work, the concentration of

ammonium bicarbonate buffer, the choice of organic modifiers, as well as the percent
content of the organic modifier were optimized for the separation and detection of
triapine and the IS. !
!

!
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Figure 2.7, Effect of organic modifier in mobile phase on LC separation of triapine and
the internal standard. (A) a mixture of triapine (1.00 x 103 ng mL-1) and the IS (200 ng
mL-1) which was prepared in a mobile phase containing 18% acetonitrile and 82%
ammonium bicarbonate (10.0 mM, pH 8.5) (v/v), and separated using the same mobile
phase; and (B) a mixture of triapine (1.00 x 103 ng mL-1) and the IS (200 ng mL-1),
which was prepared in a mobile phase containing 30% methanol and 70% ammonium
bicarbonate (10.0 mM, pH 8.5) (v/v), and separated using the same mobile phase.
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Four concentrations of ammonium bicarbonate (5.00, 10.0, 25.0, and 50.0 mM,
pH 8.5) were examined. It was found that the concentration of ammonium bicarbonate
not only affected the peak heights but also the shapes of triapine and the IS. The higher
the concentration of ammonium bicarbonate was, the higher the peaks and the longer
peak tailing were (data were not shown). The optimum concentration of ammonium
bicarbonate was found to be 10.0 mM, which yielded good peak heights and symmetries
to triapine and the IS. Furthermore, two organic modifiers, acetonitrile and methanol,
were tested. It was found that acetonitrile was the better one since it resulted in greater
separation efficiency and detection sensitivity for triapine and the IS. As shown in Figure
2.7, the chromatographic peaks of triapine and the IS using a mobile phase containing
18% acetonitrile and 82% ammonium bicarbonate (10.0 mM, pH 8.5) (Figure 2.7A) were
not only sharper with shorter retention times, but also 25% larger than those using a
mobile phase containing 30% methanol and 70% ammonium bicarbonate (10.0 mM, pH
8.5) (Figure 2.7B). Therefore, the former one was chosen as the mobile phase for the
LC-UV method.
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Table 2.1, Effect of EDTA concentration in the mobile phase on the chromatographic
peak area of triapine
!
[Triapine]
[EDTA] Added
Peak Area
Recovery (%)a
(ng mL-1)
(mM)
0.00
504478
100
1.00
544331
108
5.00
549881
109
1.00 x 103
10.0
550890
109
25.0
544332
108
50.0
553917
110
a
Recovery (%) = {peak area at [EDTA] ≠ 0/peak area at [EDTA] = 0} x 100%
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2.3.2.3. Optimization of EDTA concentration
As discussed in the section 2.3.1.3, EDTA is a stronger chelator to metal ions than
triapine. If both EDTA and triapine are present in a solution, metal ions prefer to react
with EDTA, leading to triapine uncomplexed. The addition of EDTA to a mobile phase
could eliminate the interference of metal ions present in reagents, solvents, column, and
instrument on the measurement of triapine. In this work, the concentration of EDTA in
mobile phase was optimized using six EDTA concentrations (0.00, 1.00, 5.00, 10.0, 25.0
and 50.0 mM), and the results were summarized in Table 2.1. Compared to a mobile
phase (18% acetonitrile and 82% 10.0 mM ammonium bicarbonate at pH 8.5) without
EDTA, the mobile phase containing 1.00 mM EDTA could increase the peak area of
triapine by 8% at triapine concentration of 1.00 µg mL-1. The mobile phase containing
higher EDTA concentrations (5.00-50.0 mM) did not further increase the peak area of
triapine significantly. Therefore, 5.00 mM EDTA was added to the mobile phase for the
LC-UV method.

2.3.3. LC-UV method validation
From the studies of previous sections, it was concluded that the optimized
conditions for the determination of triapine by the LC-UV method included the
followings: a Waters X-Terra RPC 18 column, a mobile phase containing 18%
acetonitrile and 82% ammonium bicarbonate-EDTA buffer (10.0 mM ammonium
bicarbonate and 5.00 mM EDTA at pH 8.5) pumped at a flow rate of 0.200 mL/min, and
a UV detector set at wavelength of 360 nm. These conditions were then applied to the
method validation. The representative chromatograms of triapine in solution at various
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concentrations (0.00, 3.00, and 30.0 ng mL-1) were given in Figure 2.8. As shown in the
figure, a complete baseline resolution of triapine and the IS was achieved. The retention
times of triapine and the IS were 4.7 min and 6.4 min, respectively; and the total
chromatographic runtime was 8.5 min.

!

74!

!
A

Intensity (mAU)

1250
1050
850
650
450
250
50
-150
0

Intensity (mAU)

1250

4

6

8

10

8

10

8

10

IS

B

1050

!

850
650
450

Triapine

250
50
-150
0
1250

Intensity (mAU)

2

2

4

!

IS

C

1050

6

Triapine

850
650
450
250
50
-150
0

!

2

4

6

Time (min)

!

Figure 2.8, Representative liquid chromatograms of triapine and the IS. (A) Blank; (B) at
LLOQ of the method, where [triapine] = 3.00 ng mL-1 and [IS] = 100 ng mL-1; and (C)
[triapine] = 30.0 ng mL-1 and [IS] = 100 ng mL-1. The LC-UV method was described in
Section 2.5
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IS

2.3.3.1. Calibration curve and the lower limit of quantitation
Internal calibration was used for quantitation of triapine, which was done using
one zero (i.e., mobile phase) and six non-zero triapine calibrators (3.00, 10.0, 30.0, 100,
300, and 1.00 x 103 ng mL-1) along with the IS in each at fixed concentration (100 ng
mL-1).

In this work, a linear calibration range of 3.00-1.00 x 103 ng mL-1 was

established by plotting the peak-area ratios of triapine to the IS versus the concentrations
of triapine. The calibration equation derived from three validation batches using 1/x2
weighted linear regression was Y = 0.022 (± 0.001) X − 0.017 (± 0.002) (where Y is the
peak area ratio of triapine to the IS and X is the concentration of triapine) with a
coefficient of determination (r2) of 0.999 (± 0.001). The accuracy and precision of each
individual calibrator expressed as percent relative error (%RE) and coefficient of
variation (%CV) were summarized in Table 2.2, which ranged from -3% to 4%, and 0.1%
to 4%, respectively. The lower limit of quantitation (LLOQ) was defined by the lowest
calibrator in the calibration curve, which had signal-to-noise (S/N) ratio of 13.5 by the
mean peak areas.
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Table 2.2, Accuracy and precision of triapine calibrators over three validation batches.
Nominal
[Triapine]
(ng mL-1)
3.00
10.0
30.0
100
300
1.00 x 103

Mean
Measured
[Triapine]
(ng mL-1)
3.08
9.69
29.8
100
306
1.04 x 103

Standard
Deviation
(ng mL-1)

Precision
(%CV)

Accuracy
(%RE)

0.09
0.4
1
2
0.3
3

3
4
4
2
0.1
0.3

3
-3
-0.6
0.1
2
4

Calibration equations: Y = 0.022 (± 0.001) X − 0.017 (± 0.002), r2 = 0.999 (±0.001)
%CV = (standard deviation/mean measured) x 100%
%RE = [(mean measured - nominal)/nominal] x 100%
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2.3.3.2. Accuracy and precision
The intra-assay accuracy and precision were determined by five replicate
measurements of each QC sample at the concentrations of 3.00, 9.00, 90.0, and 900 ng
mL-1 (i.e., LLOQ, LQC, MQC and HQC) within a validation batch. The inter-assay
accuracy and precision were determined by five parallel measurements of 5 identical QC
samples at the concentrations of 3.00, 9.00, 90.0, and 900 ng mL-1 over five validation
batches. As summarized in Table 2.3, the intra-assay accuracy and precision ranged -3%
- 7% and 1% - 3%; and the inter-assay accuracy and precision ranged -3% - 9% and 2% 4 %, respectively.

2.3.3.3. Stability
The stability of triapine in solution was evaluated using both LQC (9.00 ng mL-1)
and HQC (900 ng mL-1). The stability was determined by the percent recovery which
was calculated by the mean-peak-area ratio of triapine to the IS from three parallel
measurements of three identical QC samples over that of the freshly prepared QC
samples. As shown in Table 2.4, the recoveries of triapine under various test conditions
such as on bench top (23 °C, up to 24 h), in oven (90 °C, up to 24 h), by three freeze-andthaw cycles (-20 °C to 23 °C), and by long-term storage (-20 °C for 30 days) were from
90% to 105%, which indicated that triapine solution was very stable under the test
conditions.
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Table 2.3, Intra- and inter-assay precision and accuracy {n = 5, [IS] = 100 ng mL-1}
Assay
Nominal
Mean
Standard
Precision Accuracy
[Triapine]
Measured
Deviation
(%CV)
(%RE)
(ng mL-1)
[Triapine]
(ng mL-1)
(ng mL-1)
Intra3.00 (LLOQ)
2.79
0.03
1
7
assay
9.00 (LQC)
8.66
0.2
2
4
90.0 (MQC)
93.0
0.9
1
-3
900 (HQC)
854
0.3 x 102
3
5
Inter3.00 (LLOQ)
2.72
0.1
4
9
assay
9.00 (LQC)
9.27
0.2
2
-3
90.0 (MQC)
92.9
2
2
-3
2
900 (HQC)
843
0.2 x 10
2
6
!
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Table 2.4, Stability study of triapine under various conditions
Conditions

Temperature
(°C)

Bench-top

22

Oven

90

Freezethaw (3
cycles)
Long-term
(30 days)

-20 to 22
-20

LQC
HQC
LQC
HQC
LQC

Recovery ± SD (%) (n = 3)
4h
8h
24 h
97 ± 1
105 ± 3
100 ± 1
99 ± 1
99 ± 1
101 ± 1
103 ± 2
104 ± 2
93 ± 1
99 ± 1
100 ± 1
90 ± 1
100 ± 1

HQC
LQC
HQC

97 ± 1
102 ± 3
101± 2

QCs

The concentrations of triapine in the LQC and HQC were 9.00 and 900 ng mL-1,
respectively; and the concentration of the IS was 100 ng mL-1.

!

80!

2.4.

Conclusion
An LC-UV method for the quantitative determination of triapine has been

developed and validated through understanding the chemical equilibria and complexation
reaction of triapine in aqueous solution. The effects of pH, EDTA, metal ions, and buffer
composition on UV-visible absorption spectra of triapine were investigated. In addition,
LC separation, as well as UV detection of triapine were optimized.
developed

in

this

work

employed

The method

2-[(3-methoxy-2-pyridinyl)methylene]

hydrazinecarbothioamide as internal standard, Waters Xterra RP18 as separation column,
18% acetonitrile and 82% ammonium bicarbonate-EDTA buffer [10.0 mM (NH4)HCO3
and 5.00 mM EDTA (v/v) at pH 8.5] as mobile phase, and UV wavelength of 360 nm for
detection. This method had a linear calibration range of 3.00-1.00 x 103 ng mL-1 for
triapine, an accuracy (%RE) of ≤ ±9%, and a precision (%CV) of ≤ 4%.
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CHAPTER III
QUANTITATIVE ANALYSIS OF TRIAPINE, AN INHIBITOR OF
RIBONUCLEOTIDE REDUCTASE, IN HUMAN PLASMA BY LIQUID
CHROMATOGRAPHY TANDEM MASS SPECTROMETRY

3.1.

Introduction
As discussed in previous chapter, triapine is a potent inhibitor of ribonucleotide

reductase. Compared with hydroxyurea (HU), which is the only RR inhibitor currently
used in chemotherapy in vitro, triapine was shown to have significantly higher potency
and a broader-spectrum antitumor activity. Studies show that triapine is 1000-fold more
potent than HU [1] ; can significantly decrease RR activity in a variety of cancer cell
lines including leukemia, non-small-cell lung cancer, renal cancer and melanoma; and
enhances radiation-mediated cytotoxicity in cervical and colon cancers [1-6] . These
promising pre-clinical data have prompted the initiation of a number of clinical trials. So
far, triapine has been studied in 35 clinical trials in the USA at various stages of
recruitment (www.clinicaltrials.gov), including those in treatment of both hematologic
and solid malignancies. In particular, there are four trials investigating the radio
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sensitizing potential of triapine being published by Kunos et al. [7-10] .
Despite of therapeutic importance of triapine, there is no publication available on
analytical method development and validation for this important compound. Although
liquid chromatographic assays were mentioned for the measurement of triapine in clinical
studies [11-13] , these assays suffered from low sensitivity, poor selectivity, and
irreproducibility when being repeated. The difficulty in developing a quantitative assay
for triapine is due to the chemical nature of triapine. As a chelator and a weak acid,
triapine has multiple equilibra in aqueous solution, which are affected by various factors.
In our previous study, the effects of pH, buffer composition, and EDTA, as well as other
metal ions on the spectral absorptivity and chromatographic retention of triapine have
been investigated [14] . Adding ammonium bicarbonate and EDTA to both mobile phase
and the solvent of dissolving trapine could solve the metal ion interference problem.
Although an LC-UV based assay to quantify triapine has been developed in our lab
[14] , it often suffered from low sensitivity. In clinical samples such as blood and tissue,
the quantity of triapine can be very low, requiring the highly sensitive assays for its
quantification. Moreover, clinical samples are highly complex and even the welldeveloped LC condition may not be able to completely separate this analyte molecule
from some of other molecules present in clinical samples. In other words, the molecules
that have the retention time similar to that of triapine may interfere UV measurements of
triapine.
In this work, a sensitive, accurate, and reliable HPLC-MS/MS assay was developed
for

the

quantitative

analysis

of

triapine.

The

assay

used

2-[(3-fluoro-2-

pyridinyl)methylene]-hydrazinecarbothioamide (NSC# 266749) (Figure 3.1B) as internal
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standard (IS). Tripaine and the IS were separated on a Waters Xbridge Shield RP 18
column (3.5 µm; 2.1 × 50 mm) using 25.0% methanol and 75.0% ammonium bicarbonate
buffer (10 mM, pH 8.5) (v/v) as mobile phase. This is the first validated LC-MS/MS
method for the quantification of triapine in human plasma and we have successfully
applied it to the measurement of triapine in patients’ samples.
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Figure 3.1, The chemical structures of (A) triapine and (B) NSC 266749, the internal
standard of LC-MS/MS method.
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3.2.

Experimental

3.2.1. Chemicals and solutions
Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone or 3-AP) was
kindly provided by Vion Phamaceuticals (New Haven, CT, USA) and used as chemical
standard of the analyte. 2-[(3-fluoro-2-pyridinyl)methylene]-hydrazinecarbothioamide
(CAS No. 31181-41-6 or NSC# 266749) was obtained from the Developmental
Therapeutics Program of the National Cancer Institute at the National Institutes of Health
(Bethesda, MD, USA) and used as the internal standard (IS) for triapine in the LCMS/MS method. HPLC-grade methanol, ethylenediaminetetraacetic acid disodium salt
(EDTA), and ammonium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Ammonium bicarbonate was from EMD Chemicals (Darmstadt, Germany).
Deionized water was obtained from a Barnstead Model 7148 Nanopure® ultrapure water
system of the Thermo Scientific (Asheville, NC, USA). 6 different lots of human plasma
with sodium EDTA and 6 different lots of human serums were purchased from
Innovative Research (Novi, MI, USA).
The working solvent was prepared by mixing 25.0% acetonitrile and 75.0%
ammonium bicarbonate-EDTA buffer (i.e., 10 mM (NH4)HCO3 and 1 mM EDTA (v/v) at
pH 8.5). The standard stock solutions of triapine and IS were prepared in methanol at a
concentration of 1 mg/mL, respectively and kept at −20 °C before use. Working standard
solution of triapine (1.00 µg/mL) and working solution of the IS (1.00 µg/mL) were
freshly prepared by serial dilution of each stock solution with a working solvent. The
mobile phase for liquid chromatographic separation was prepared by mixing methanol
and 10.0 mM ammonium bicarbonate (pH 8.5) at a ratio of 25:75 (v/v).
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3.2.2. Instrumentation
The instrumentation system used consisted of a Shimadzu SIL-20AC autosampler
(Shimadzu, Columbia, MD, USA), a Shimadzu LC-20AD HPLC unit with Waters
Xbridge Shield RP 18 column (3.5 µm; 2.1 × 50 mm), and an AB Sciex API 3200 turboion-spray® triple quadrupole tandem mass spectrometer (AB Sciex, Foster City, CA,
USA). The system was controlled by AB Sciex Analyst® (version 1.5.1) software. The
API 3200 tandem mass spectrometer was operated under the positive turbo-ion-spray
ionization mode.
It was tuned by a mixture f 500 ng/ml tiapine and 500 ng/mL IS in 50% methanol
and 50% ammonium bicarbonate (10 mM, pH 8.5) for both the compound dependent and
the source-dependent parameters. MRM data were acquired with the following mass
transitions and optimized instrument settings: m/z 196 > 121 for triapine and m/z 199 >
124 for the IS; curtain gas (CUR) at 40, collision assisted dissociation gas (CAD) at 8;
ionization voltage (IS) at 4500 V; source temperature (TEM) at 700; sheath gas (GS1) at
50; desolvation gas (GS2) at 40; desolvation potential (DP) at 40; entrance potential (EP)
at 4; collision energy (CE) at 23; collision cell exit potential (CXP) at 2; and resolution at
unit.
Analytical separation of the analytes was accomplished on a Waters Xbridge
Shield RP 18 column by isocratic elution with the mobile phase at a flow rate of 0.30
ml/min. Prior to initial sample analysis, the column was equilibrated with the mobile
phase at the above flow rate for at least 30 min. During each run, 10 µL of reconstituted
sample was injected into the system by the autosampler set at 4 ◦C. The two-position
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switch valve on the API 3200 tandem mass spectrometer was programmed to the switch
to the waste for the first 1.2 min and then switch to the mass spectrometer. Quantitation
of the analytes was carried out with MRM mode of the tandem mass spectrometer. The
total instrument run time for each sample analysis was 4 min.

3.2.3. Preparation of standard solutions, plasma calibrators and controls, and patients’
plasma samples
Triapine standard solutions (5.00, 10.0, 15.0, 20.0, 50.0, 100, 150, 200, 500, 800,
and 1000 ng/mL) and IS standard solution (100 ng/mL) were prepared by serial dilution
of triapine working solution (1.00 µg/mL) and IS working solution (1.00 µg/mL) with
working solvent, respectively.
Ttiapine plasma calibrators (0.25, 0.50, 1.00, 2.50, 5.00, 10.0, 25.0, and 50.0
ng/mL) were prepared individually by mixing 200 µL of pooled blank plasma, 10.0 µL of
triapine standard solution (at 20 times of the calibrator’s concentration), and 10.0 µL of
IS standard solution at 100 ng/mL.
Triapine plasma controls (0.75, 7.5, and 40.0 ng/mL) prepared by mixing 200 µL
of pooled blank plasma, 10.0 µL of triapine standard solution (at 20 times of the
calibrator’s concentration), and 10.0 µL of IS standard solution at 100 ng/mL.
Patients’ samples were prepared by mixing 200 µL of blood sample, 10.0 µL of
working solvent and 10 µL of IS standard solution at 100 ng/mL.

3.2.4. Sample extraction
Plasma calibrators, controls and patients’ samples prepared as described in
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Section 2.2.3 were extracted using the following protocol: each sample was deproteinized
with ACN at a ratio of 4 to 1 by vortex mixing for 30 s; followed by centrifugation at
15000 x g for 10 min, the supernatant was pipetted into a 1.5-mL microcentrifuge tube
and dried in a TurboVap® LV evaporator (Caliper Life Sciences, Hopkinton, MA, USA)
at 30 ◦C under nitrogen gas. Finally, the residue was then reconstituted in 110 µL of
working solvent for LC-MS/MS analysis.

3.2.5. Stability
The stability of triapine solution at two concentrations (1.00 mg/mL and 1.00
µg/mL) were carried out by leaving the test controls at bench top (23 ◦C) for 6 and 24 h.
The stability of triapine in human plasma before and after sample preparation, and
through freeze-and-thaw cycles were investigated at low and high QC concentrations
(0.75 and 40.0 ng/ml). These studies included QC samples kept on bench top at 23 ◦C for
6 and 24 h before sample preparation and analyses, QC samples kept in autosampler at 4
◦C for 6 and 24 h after sample preparation and before LC–MS/MS analyses, QC samples
undergone three freeze-and-thaw cycles where the samples were frozen at −20 ◦C for at
least 24 h and thawed at room temperature unassisted 3 times and QC samples stored at
−20 ◦C for 30 days prior to analysis for long term stability study. All experiments were
run in triplicate and the results were compared with freshly prepared triapine solutions
and plasma controls.
Similarly, the stability of IS solution (100 ng/ml) at bench top (23 ◦C), and the
stability of IS in human plasma (5.00 ng/mL) at bench top (23 ◦C) and in autosampler (4
◦C) were investigated. All experiments were run in triplicate and the results were
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compared with controls, which were freshly prepared IS in solution and in human
plasma.

3.3.2. Method application
The feasibility of the method developed was tested by measuring triapine
concentration in advanced cervical cancer patients. Dr. Charles A. Kunos at Case
Comprehensive Cancer Center, Case Western Reserve University provided the patients
samples to be analyzed. In this study, all 6 patients enrolled have been histologically
confirmed primary or recurrent gynecologic malignancies not amenable to curative
surgery. Triapine was supplied by Vion Pharmaceuticals to NCI-CTEP in 50-mg viscous
liquid vials and was diluted in 0.9% sodium chloride to a final concentration of 0.01 to 2
mg/mL. Patients were given triapine as a 2-h i.v continuous infusion (25 mg/m2) three
times weekly. Heparinized intravenous blood samples on day 1 and day 10 before and at
2, 4, 6, and 24 h after start of 2-h infusion were drawn to determine triapine
concentrations. Plasma was centrifuged at 3,000 rpm (15 min) in a refrigerated centrifuge
and then stored (−80°C).

3.3.

Results and Discussion

3.3.1. Method development
3.3.1.1. Mass spectrometric detection
In this work, the optimization of triapine and 2-[(3-fluoro-2-pyridinyl)
methylene]-hydrazinecarbothioamide (IS) responses was done using the “auto-tune”
function of AB Sciex Analyst software (version 1.5.1). Since triapine and the IS were
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easier to form protonated species than deprotonated species by electrospray ionization,
the positive electrospray-ionization mode was used for the triapine identification and
quantification. As shown in Figure 3.2A and C (the m/z scan by the first quadrupole),
tirapine and the IS produced predominant molecular ions at m/z 196 for [triapine+H]+
and m/z 199 for [IS+H]+, respectively. These molecular ions produced were further
dissociated into fragment ions by collision with nitrogen gas in the second quadrupole
(Figure 3.2B and D). The predominant fragment ions of [triapine+H]+ and [IS+H]+ were
m/z 121 and m/z 124, respectively. Therefore, the mass transition pairs m/z 196 > 121 for
triapine and m/z 199 > 124 for the IS were chosen for quantification in the multiplereaction-monitoring (MRM) mode.
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Figure 3.2, The mass spectra of triapine and the internal standard. The experimental
conditions were the same as those described in Section 3.2.2.
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3.3.1.2. Triapine Solution Preparation
When we first started the method development, the irreproducibility issue was
found. We prepared different batches of triapine at the concentration of 1.0 ng/mL in
25% MeOH and 75% water (v/v), but it was observed that the triapine ion signals varied
dramatically from batch to batch. After trouble shooting, we found that the
irreproducibility problem was due to the deionized water system that we used. If the
samples were prepared by using bottle water (ultrapure, HPLC Grade), the results were
highly reproducible. As discussed in the introduction part, triapine is a metal chelator,
which can coordinate with metal ions. Although our water system met the water
purification standard, trace amounts of metal ions remained in the deionized water could
still interfere with the detection of triapine. Considering the difficulty of controlling the
quality of water sources, and the possibility of introducing metal ions from other sources,
we attempted to develop a simple, but reliable method to minimize the metal ion
interference.
In our previous study [14], it was found that metal ions preferentially bonded with
EDTA, leaving triapine unreacted, and that metal ions could be precipitated in the
presence of high concentration of ammonium bicarbonate. It was expected that adding
ammonium bicarbonate and EDTA to both mobile phase and the solvent of dissolving
trapine might solve the metal ion interference problem. In this work, we first attempted to
use this strategy to solve the problem, but failed due to the fact that the presence of
EDTA in mobile phase could suppress the triapine ion signal by more than 20 times. We
then only added EDTA to the solvent of dissolving trapine and found that the triapine ion
signal was not suppressed. More importantly, the ion signal of triapine became highly
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reproducible when we prepared different batches by using the same water purification
system. Therefore, in the remaining of this study, only ammonium bicarbonate (10 mM,
pH 8.5) was added to mobile phase A, while an ammonium bicarbonate-EDTA buffer
(i.e., 10 mM (NH4)HCO3 and 1 mM EDTA at pH 8.5) was added to the solvent of
dissolving triapine.

3.3.1.3. Liquid chromatographic separation
In this work, several analytical columns were tested for development of this
quantification method. Separation of triapine and the IS was tested on Waters X-Terra RP
18 (2.1 mm x 150 mm, 5 µm particle size), Waters X-Bridge RP 18 (2.0 mm × 50 mm, 5
µm particle size), Waters X-Bridge AQ (2.0 mm × 50 mm, 5µm particle size), and
Waters X-Bridge Phenyl (2.0 mm × 50 mm, 5µm particle size) columns with a mobilephase flow rate of 0.300 mL/min. Although reasonable retention time and sufficient
resolution were observed on all columns tested, Waters X-Bridge RP 18 column was
chosen for the method development because it led to a greater signal response and better
peak shape.
Furthermore, two organic modifiers, acetonitrile and methanol, were tested. It was
found that methanol was the better one since it resulted in a greater separation efficiency
and detection sensitivity for triapine and the IS. Finally, the optimal separation of triapine
and the IS was achieved on a Waters X-Bridge RP 18 (2.0 mm × 50 mm, 5 µm particle
size) column at 1.6 and 1.9 min by a mobile phase containing 25.0% methanol and 75.0%
ammonium bicarbonate buffer (10 mM, pH 8.5) (v/v) (Figure 3.3).
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3.3.1.4. Biological sample selection and extraction
Serum and plasma are two common biological sources. In this study, both serum
and plasma were tested in order to determine which one would be the better source when
we analyzed triapine in clinical studies. Triapine plasma and serum samples were
prepared by spiking triapine in six lots of blank human plasma and six lots of blank
human serum. Three extraction methods including protein precipitation by ACN and
methanol, and liquid-liquid extraction by acetyl acetate were tested to extract triapine
from serum and plasma. This testing study showed that the ion signal intensity of triapine
extracted from serum was significantly lower than the signal of triapine extracted from
plasma. The absolute recovery of triapine by 3 extraction methods and the matrix effect
in plasma and serum were summarized in Figure 3.4. The absolute recovery was
calculated by comparing the mean peak area of the triapine samples prepared by spiking
it to matrix before and after extraction. The sample matrix effect was evaluated with the
absolute matrix factor, which is the mean peak area of triapine in the extracted matrix
over the pure solution. As shown in Figure 3.4A, the recoveries of triapine in serum were
lower than that in plasma. More importantly, as shown in Figure 3.4B, the matrix factors
ranged from 0.75 – 0.80 and 0.12 – 0.20 in plasma and serum, respectively, indicating
that triapine in serum suffered from a serious matrix effect. Therefore, after extraction,
triapine extracted from plasma had a higher intensity that that extracted from serum.
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Figure 3.3, Representative MRM chromatograms of human plasma: (A) double blank;
(B) 0.25 ng/mL triapine in plasma with 5.0 ng/mL IS; and (C) 2.5 ng/mL triapine in
plasma with 5.0 ng/mL IS.
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Figure 3.4, The comparison of recovery and matrix effect of triapine in human plasma
and serum by using different extraction metods. Each column represents the mean ±SD in
six lots.
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Furthermore, as anticoagulants, EDTA is added to whole blood to prepare plasma,
and as we discussed previously, EDTA can effectively inhibit the unwanted chelation
reaction involving trianpie. Therefore, this study suggested that plasma was the biological
source of choice when quantifying triapine for clinical trials.
In addition, three extraction methods were compared in this study. Based on this
comparison study, protein precipitation by 4 times of ACN was selected for the
remaining of this work because it is simple and has a highest recovery.

3.3.2. Method validation
3.3.2.1. Sensitivity and lower limit of quantification (LLOQ)
The selectivity of the quantification method developed was determined by
comparing the chromatograms of six lots of blank plasma samples with those of the
spiked plasma calibrator at the LLOQ. In this work, there were no endogenous
interference observed at the retention times and mass transitions of triapine and the IS
(Figure 3.3A).
The LLOQ of the method was defined by the lowest calibrator (0.25 ng/mL) of
the calibration curve (Fig. 3B). The precision and accuracy of each lot of plasma at
LLOQ were calculated based on five separate samples with one injection per sample. The
data are summarized in Table 3.1. The accuracy and the precision of the method at the
LLOQ were ≤ ±10% and ≤ 7%.
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Table 3.1. Accuracy and precision of triapine at LLOQ in six individual lots of human
plasma matrices
Nominal
Mean measured
SDa
[Triapine]
[Triapine]
(ng/mL)
(ng/mL)
(ng/mL)
Lot 1
0.250
0.225
0.004
Lot 2
0.250
0.26
0.02
Lot 3
0.250
0.26
0.01
Lot 4
0.250
0.248
0.007
Lot 5
0.250
0.261
0.007
Lot 6
0.250
0.250
0.008
a
SD = standard deviation
b
%CV = (SD/mean) x 100%
c
%RE = [(measured – nominal)/nominal] x 100%
Plasma
matrix
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Precision
(%CV)b

Accuracy
(%RE)c

2
8
4
3
3
3

-10
4
4
-1
5
-0.1

3.3.2.2. Matrix effect and recovery
The matrix effect and extraction efficiency were evaluated at three levels: 0.750,
7.50 and 40.0ng/mL. Matrix factor was calculated by comparing the mean-peak-area
ratios of triapine to the IS in the QC samples prepared by spiking the analytes after
plasma deproteinization to those prepared in the mobile phase. Recovery was calculated
by comparing the mean-peak-area ratios of triapine to the IS of corresponding QC
samples prepared by spiking the analytes to plasma matrix before and after plasma
deproteinization. As shown in Table 3.2, the absolute matrix effect at three
concentrations ranged from 0.73 to 0.79, and the IS normalized matrix effect ranged from
1.03 to 1.06. Hence, the matrix suppression or enhancement of the analytical signals by
plasma was no significant and could be neglected after normalization with the IS. The
absolute recoveries of triapine were consistent between 89% and 93%, while the IS
normalized recoveries were between 101% and 104%, indicating that deproteinization by
4 volumes of acetonitrile was sufficient to recover triapine from plasma.

3.3.2.3. Linearity
Triapine calibration curves were established using double blank (blank plasma
sample with neither triapine or IS), single blank (blank plasma with IS only), and eight
nonblank calibration standards at the concentrations of 0.25, 0.50, 1.0, 2.5, 5.0, 10, 25
and 50ng/ml. The IS concentration in zero blank and the calibrations standards was
5ng/mL. The peak area ratio of triapine to IS (y) vs triapine concentration (x) was plotted
using 1/x as a weighting factor. The linear regression equation obtained in five different
days was Y = 0.373 (± 0.012) x - 0.00107 (± 0.00034). The linearity was excellent over
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the range of 0.25 to 50 ng/mL with the correlation coefficients above 0.999 for all
calibration curves built on different days. The accuracies and precisions of all calibrators
were summarized in Table 3.3, where accuracy ranged -3–6% and precision was 4–8%,
respectively.

3.3.2.4. Accuracy, precision and dilution integrity
Inter-assay precision and accuracy were assessed by five parallel injections from
five identical QC samples at each concentration. Intra-assay precision and accuracy were
assessed by five replica measurements of each QC samples. As shown in Table 3.4, the
intra- and inter assay accuracy and precision were within ±10%, indicating that this
method is accurate, precise and reproducible. Since some samples containing triapine
were found above the highest concentration of calibration curve, we also investigated the
accuracy and precision after 10-fold dilution of the QC at the concentration of 400
ng/mL. The results showed that the intra- and inter-accuracy of the diluted sample were
1% and 7%. The intra- and inter-precision were 4 and 7%. These results indicated that
diluting the samples that had concentrations above the upper limit of the calibration curve
would not lead to significant errors in the measurement of the triapine concentrations.
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MFIS ± SD
0.72 ± 0.02
0.69 ± 0.02
0.71 ± 0.02

MFtriapine ± SD
0.74 ± 0.03
0.73 ± 0.01
0.79 ± 0.02

IS Normalized
MF ± SD
1.03 ± 0.05
1.06 ± 0.03
1.04 ± 0.03

Recovery triapine
± SD (%)
89 ± 5
91 ± 2
93 ± 3

Recovery IS
± SD (%)
88 ± 5
88 ± 3
89 ± 2

IS Normalized Recovery ±
SD (%)
101 ± 8
103 ± 4
104 ± 4

IS Normalized Recovery = (Recoverytriapine/ RecoveryIS) x 100%.

100%; RecoveryIS = [(mean peak area of IS in plasma matrix)/(mean peak area of IS in extracted plasma matrix)] x 100%; and

Recoverytriapine = [(mean peak area of triapine in plasma matrix)/(mean peak area of triapine in extracted plasma matrix)] x

peak area of IS in extracted plasma)/(mean peak area of IS in mobile phase); and IS Normalized MF = MFtriapine/MFIS.

MFtriapine = (mean peak area of triapine in extracted plasma matrix)/(mean peak area of triapine in mobile phase); MFIS = (mean

[Triapine]
(ng/mL)
0.75
7.50
40.0

Table 3.2. Matrix factor and recovery of triapine in pooled human plasma (n = 5)

Table 3.3, Accuracy and precision of triapine plasma calibrators over six validation
batches.
Nominal
[Triapine]
(ng/mL)
0.25
0.50
1.00
2.50
5.00
10.0
25.0
50.0

!

Mean Measured
[Triapine]
(ng/mL)
0.25
0.50
0.98
2.5
4.9
9.8
24
53

SD
(ng/mL)

Precision
(%CV)

Accuracy
(%RE)

0.01
0.03
0.08
0.1
0.4
0.5
2
2

4
6
8
4
8
5
8
4

1
0.1
-2
1
-2
-2
-4
6

107!

Table 3.4, Intra- and inter-run accuracy and precision of triapine in pooled human plasma
(n = 5)
Intra-Run a
Nominal
[Triapine]
(ng/mL)
0.75
7.50
40.0
400.

Measured
[Triapine]
(ng/mL)
0.74
8.1
40.
406 c

SD
(ng/mL)
0.02
0.1
2
2
Inter-Run b

Precision
(%CV)

Accuracy
(%RE)

3
1
5
1

-1
8
-1
2

Nominal
Measured
SD
[Triapinw]
[Triapine]
%CV
%RE
(ng/mL)
(ng/mL)
(ng/mL)
0.75
0.72
0.01
1
-4
7.50
7.0
0.3
4
-7
40.0
38.2
0.9
2
-4
c
400.
429
3
1
7
a
Each datum point was calculated by five replicate measurements of each QC sample
within a validation batch.
b
Each datum point was calculated by five parallel measurements of five identical QCs at
each concentration over five validation batches.
c
The dilution QC was measured by a 10-fold dilution.
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Table 3.5, Stability studies of triapine and the IS under various conditions (n = 5)
Nominal
[triapine]
(ng/mL)
1.00 X 106
Stock solution
23
1.00 X 103
0.75
Bench-top
23
40.0
0.75
Autosampler
4
40.0
3 Freeze-thaw
0.75
-20 to 23
cycles
40.0
Long-term (30
0.75
-20
days)
40.0
Nominal
Test
Temperature
[IS]
conditions
(°C)
(ng/mL)
Stock solution
23
100
Bench-top
23
5.00
Autosampler
4
5.00
3 Freeze-thaw
-20 to 23
5.00
cycles
Long-term (30
-20
5.00
days)
Test
conditions
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Temperature
(°C)
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Recovery ± SD (%)
6h

24 h

101 ± 1
106 ± 3
88 ± 2
90 ± 2
96 ± 1
87 ± 1

100 ± 4
100 ± 5
68 ± 3
61 ± 5
94 ± 8
83 ± 5
96 ± 2
98 ± 5
86 ± 6
91 ± 5

Recovery ± SD (%)
6h

24 h

105 ± 2
89 ± 5
87 ± 3

100 ± 6
84 ± 5
93 ± 5
92 ± 4
88 ± 7

3.3.2.5. Stability
The results of the stability study are summarized in Table 3.5. At room
temperature, tiapine and the IS stock solutions were found to be stable at least 24 h. The
bench-top studies shown that triapine and IS in plasma before deproteinization were
stable at room temperature up to 6 h. The post-extraction stability study of tiapine and the
IS indicated that they were stable in the reconstitution solvent for at least 24 h in the
autosampler at 4°C.
After three freeze–thaw cycles, the recovery of triapine was 96% at LQC and 98%
at HQC levels and the recovery of the IS was 92%. Moreover, there was no significant
loss of triapine and the IS observed in the long-term storage stability study.

3.3.3. Application
The feasibility of using this method in clinical studies was tested by the
measurement of triapine in advanced cervical cancer patients’ samples, which were
provided by Dr. Charles A. Kunos at Case Comprehensive Cancer Center. In this work,
the samples collected together with ten calibrators (i.e., one single-blank, one doubleblank and eight nonzero) and a set of QCs at low-, mid- and high-concentrations (i.e.,
0.750, 7.50 and 40.0 ng/mL) were extracted after adding the IS solution by following the
procedure described in Section 3.2.6, and analyzed by the validated method. For the
samples having the concentration higher than the upper limit of calibration curve (i.e., 50
ng/mL), they were analyzed again after 1:10 dilution using the pooled blank human
plasma together with the dilution QC at the concentration of 400 ng/mL. Figure 3.5
shows the triapine concentration–time profile in patient blood after start of 2-hour
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triapine infusion.
Compared with the results provided by Dr. Kunos’ group, which were obtained
using an LC-UV method

[9] , our LC-MS method generated a similar triapine

concentration–time profile. Moreover, Kunos’ group found that the concentration of
tirapine in the samples collected at 24 h after start of infusion on day 1 and day 10, and
before start of infusion on day 10 were below the LLOQ of the LC-UV method. In other
words, the LC-UV could not detect triapine in the samples. In contrast, our study showed
that the average concentrations of triapine in the samples were actually above the LLOQ
of our LC-MS method. Clearly, this study demonstrated that the LC-MS developed by us
is much more sensitive than the currently used LC-UV method.

3.4.

Conclusion
This chapter describes the development and validation of a LC–MS/MS method

for the quantitation of triapine in plasma. The method used a simple deproteinization
method for sample preparation, and a RP column for separation. EDTA was added in the
samples to inhibit the unwanted complexation reaction with metal ions. It has a linear
calibration range of 0.250–50.0 ng/mL and stability needed for routine analysis. The
method has been successfully applied to the measurement of triapine in the blood
samples of advanced cervical cancer patients. The method developed provides a more
sensitive and robust tool for quantification of triapine for future clinical studies.

!

111!

500
Day 1
[Triapine], ng/mL

400
Day 10
300
200
100
0
0

6

12

18

24

Time, Hr

Figure 3.5, Mean triapine concentration – time profile in 6 patients on day 1 and day 10
after start of 2-h infusion at the dose of 50 mg/m2.
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CHAPTER IV
A SPECIFIC LC-MS/MS METHOD FOR DETERMINATION OF FLUDARABINE
INCORPORATION INTO CELLULAR DNA

4.1.

Introduction
Fludarabine (9-β-D-arabino-furanosyl-2-fluoradenine monophosphate or F-ara-

AMP) is an antimetabolic agent, which is currently used in the treatment of
hematological malignancies such as CLL, AML, and non-Hodgkins lymphomas [1-3].
After administering to blood in the form of monophosphate, fludarabine is rapidly
dephosphorylated and transported to cells, where fludarabine is successively
phosphorylated to the mono, di, and triphosphate (F-ara-AMP, F-ara-ADP, and F-araATP), respectively. F-ara-ATP is the main intracellular metabolite known to have the
pharmacological activity and can ultimately lead to cellular apoptosis in both actively
dividing and resting cells [4-6]. Once F-ara-ATP was incorporated into the DNA strand,
the DNA polymerases are inhibited or forced to pause at that specific site in the DNA
strand [7].
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It has been found that the patient’s response to the fludarabine treatment varied
greatly from one patient to another patient. Since incorporation of fludarabine into DNA
is essential to cellular apoptosis, quantitation of its incorporation into cellular DNA can
lead to a better understanding of its pharmacological effect, which may in turn provide
useful information for adjustment of treatment to improve clinical outcome. In fact, there
were lines of evidence that suggested that the incorporation of fludarabine into DNA was
linearly correlated with inhibition of DNA synthesis [8].
There have been two methods reported for analysis of incorporation of
fludarabine into DNA in biological matrices [4, 9]. In the method developed by Plunkett
et al., 3H-labeled fludarabine monophosphate was used and the incorporated fludarabine
was measured by the radioactivity in the corresponding HPLC fraction [4]; whereas in
the method developed by Kemena et al., the incorporated fludarabine was first
derivatized with chloroacetaldehyde to form a fluorescent tag which was then detected by
HPLC with fluorescent detection [9]. However, both methods involved laborious sample
preparation and neither of them were validated for quantification. Moreover, the use of
radio-active isotope labeled or derivatized fludarabine is not practicable in a clinical
setting. In this paper, a novel LC-MS/MS based method to quantify incorporation of
fludarabine into DNA has been developed. Figure 4.1 displays the schematic
representation of this method. Briefly, drug treated cellular DNA was first extracted from
a biological sample such as cultured cells. The extracted DNA is then enzymatically
hydrolyzed into mono nucleosides and F-ara-A as shown in Figure 4.1. Finally, after
purification and concentration of hydrolyzed products, they are separated by LC,
followed by quantifying them with a MRM method. The validated method has been
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applied to the study of the incorporation in DNA of HL60 and CLL-MEC1 cell lines with
various fludarabine dosages. The results demonstrated that this method could readily
quantify the incorporation of fludarabine into DNA and determines variation in the
incorporation among different cell lines. Moreover this method has already successfully
been applied to measurements of the incorporation of fludarabine into cellular DNA
extracted from the blood of patients who enrolled in Case 2Y10 clinical trial.
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Figure 4.1. Schematic representation of the procedure of the LC-MS/MS method and
DNA hydrolysis by the enzymatic cocktail used in this study
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4.2.

Experimental

4.2.1. Materials and solutions
Formic

acid,

acetonitrile,

2-[Bisamino]-2-1,3-propanediol

(BisTris),

deoxyribonuclease I (DNase I), nuclease P1 (NP1), bovine alkaline phosphatase (ALP),
2′-Deoxyadenosine
Deoxyguanosine

(dA),
(dG),

2′-Deoxyadenosine
Thymidine

(T),

5′-monophosphate
2′-Deoxycytidine

(dAMP),

(dC),

2′-

2-Chloro-

2′deoxyadenosine (2CdA) and Tris EDTA (TE) buffer were obtained from SigmaAldrich (St. Louis, MO, USA). Sodium chloride (NaCl), zinc chlorides (ZnCl2),
phosphate buffered saline (PBS), water saturated phenol, optima gradient methanol and
chloroform were purchased from Fisher Scientific (Fair Lawn, NJ, USA). The 10%
sodium dodecyl sulfate (SDS) was obtained from Bio-Rad Laboratories (Hercules, CA,
USA). RPMI-1640 medium with L-glutamine was purchased from Mediatech (Manassas,
VA, USA). RNase A and protease K were ordered from Invitrogen (Carlsbad, CA, USA).
Snake venom phosphodiesterase I (PDE I) was obtained from Worthington Biochemical
Corporation (Lakewood, NJ, USA). Fetal bovine serum was purchased from Hyclone
Laboratories (Logan, UT, USA). Fludarabine (F-ara-AMP) was from Ochem (Des
Plaines, IL, USA). RiboShredder™ RNase Blend was from Epicentre Biotechnologies
(Madison, WI, USA). Deionized water was prepared by a Barnstead Model 7148
Nanopure® ultrapure water system of the Thermo Scientific (Asheville, NC, USA).

4.2.2. Cell culture and treatment
Human promyelocytic leukemia cells (HL60) were obtained from American Type
Culture Collection (Rockville, MD, USA). Chronic lymphocytic leukemia (CLL) MEC1
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cells were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany). Cells were cultured in RPMI-1640 medium supplemented
with 10% (v/v) fetal bovine serum at 37 ℃ in a humidified 5% CO2 incubator.
F-ara-AMP solutions were freshly prepared for each experiment by dissolving Fara-AMP powder in PBS (1x, pH 7.4). For each 5 × 106 cells, the dosages of F-ara-AMP
added into the culture media were 0.00, 1.00, or 10.0 µM, respectively. Cells were treated
for 2 or 24 h at 37 ℃ in a humidified 5% CO2 incubator.
After treatment, the cells were removed from the medium by centrifugation 1500
x g at 4 ℃ for 5 min, and washed with 5 mL PBS. After centrifugation (1500 x g at 4 ℃
for 5 min), the cell pellets collected were stored in -20 ℃ till DNA extraction.

4.2.3. Cellular DNA extraction
2.0 mL of TE buffer (containing 10 mM Tris and 1 mM EDTA at pH 8.0) were
added to the cell pellets. After a short vortex, 240 µL of 10% SDS solution was added
and mixed with the cell suspension gently. The lysates were treated with 20.0 µL of
RNase A (20 mg/mL dissolved in deionized water) at 37 ℃ for 1 h, followed by
treatment with 25.0 µL of protease K (20 mg/mL dissolved in deionized water). After 1 h
incubation at 37 ℃, each sample was transferred to a Phase Lock Gel tube (5 Prime,
Gaithersburg, MD) and centrifuged (4000 x g for 15min) twice with 2.0 mL of phenol,
followed by two times extraction with 2.0 mL of chloroform. After extraction, the
aqueous phase (ca. 2.0 mL) was transferred to a clean 15 mL centrifuge tube and mixed
with 10 mL of pre-chilled ethanol (-20 ℃). The DNA was precipitated at -20 ℃ for
overnight.
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After recovering the DNA pellet by removing ethanol through centrifugation
(15000 x g for 15 min), each sample was then washed with 1.0 mL of pre-cooled 70%
ethanol (-20 ℃ ). Thereafter, the samples were air-dried at room temperature and
reconstituted with TE buffer to a final concentration of 1.0 mg/mL (based on UV
absorption at 260 nm).

4.2.4. Removal of RNA
To each 100 µL of DNA sample (1.0 mg/mL), 2.00 µL of RiboShredder™ RNase
Blend (1 U/µL) was added. After 30 min incubation at 37 ℃, the sample was mixed with
1.0 mL of pre-chilled ethanol (-20 ℃).

The DNA was precipitated at -20 ℃ for

overnight. After centrifugation (15000 x g for 15 min), each sample was washed with 1.0
mL of pre-cooled 70% ethanol (-20 ℃) twice. Then each DNA sample was air-dried and
reconstituted with 200 µL of 5 mM BisTris buffer (pH 7.0).

4.2.5. Preparation of calibrators and quality control
The stock standard solutions of F-ara-AMP (4.0 mM), 2CdA (IS) (2.0 mM), and
dAMP (4.0 mM) were prepared in deionized water respectively. The working solutions of
F-ara-AMP (2.00 µM) and dAMP (2.00 mM) were prepared by diluting their stock
standard solutions with deionized waer individually. The standard working solutions of
F-ara-AMP (2.00, 6.00, 8.00, 40.0, 60.0, 80.0, 400, 800, 1800 and 2000 nM) were
prepared by serial dilution of F-ara-AMP working solution (2.00 µM). The standard
working solutions of dAMP (20.0, 30.0, 40.0, 80.0, 120, 200, 400, 600, and 800 µM)
were prepared by serial dilution of dAMP working solution (2.00 mM).
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The F-ara-A calibrators (1.00, 4.00, 20.0, 40.0, 200, 400 and 1000 nM) and the
quality controls containing F-ara-A (3.00, 30.0 and 900 nM) were prepared by mixing 25
µL of each F-ara-AMP standard working solution with 25 µL of 10 mM BisTris buffer
(pH 7.0), respectively.
The dAMP calibrators (10.0, 20.0, 40.0, 100, 200 and 400 µM) and the dAMP
quality controls (15.0, 60.0 and 300 µM) were prepared by mixing 25 µL of each dAMP
standard working solution with 25 µL of 10 mM BisTris buffer (pH 7.0), respectively.

4.2.6. Patient sample preparation
In this study, 10-mL of peripheral blood samples were collected in heparinized
Vacutainer® tubes (BD, Franklin Lakes, NJ) from a patient who enrolled in Case 2Y10
clinical trial.
At the time of blood drawing, a patient had been administered with 25 mg/m2
fludarabine plus 90 mg/m2 methoxyamine. Blood was drawn at 24, 48, 72, 96 and 168 h
after fludarabine dose was given to this patient; and the blood samples were fractioned by
Ficoll-Paque method. Briefly, 10-mL heparinized blood was layered on the top of 12 mL
Ficoll-Paque Plus reagent (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in a 50
mL sterile polypropylene centrifuge tube (RNase/DNase free); then the tube was
centrifuged at 4 °C and 300 × g for 30 min. Cells at the interface were collected and
transferred into a clean 15 mL centrifuge tube, and washed twice with 10 mL PBS (1×,
pH 7.4). In each wash step, the cells were gently vortexed with the PBS for 1 min, and
then centrifuged down at 4 °C and 300 × g for 10 min. After wash, the cell pellets were
frozen at -20 oC till DNA extraction. DNA was extracted by using the Gentra Puregene
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Blood Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol (DNA
Purification from Whole Blood or Bone Marrow Using the Gentra Puregene Blood Kit,
Gentra® Puregene® Handbook, Third Edition, June 2011, Page 19 - 21). Finally, the
extracted DNA was dissolved with a final concentration of 2 mg/mL in TE buffer.
The extracted DNA was further treated by RiboShredder™ RNase Blend (1U/µL)
to remove the RNA contaminations (See Section of 4.2.4). Finally, the purified DNA was
reconstituted with 5 mM BisTris Buffer (pH 7.0) with a final concentration of 2.0
mg/mL.

4.2.7. DNA enzyme digestion
Before hydrolysis, the DNA samples, calibrators, and quality controls were
incubated in boiling water for 30 min and chilled in ice for 15 min. Then an appropriate
volume of enzyme solutions was added to each sample. “Enzyme cocktail” were prepared
as following: DNase I was dissolved with 0.9% NaCl at the final concentration of 10
mg/mL (ca. 20000 unit/mL); NP1 was dissolved in 1 mM ZnCl2 at the final concentration
of 1 mg/mL (ca. 200 unit/mL); PDE I was dissolved with deionized water to the final
concentration of 100 unit/mL. The “enzyme cocktail” contains 10.0 µL of DNase I, 40.0
µL of PDE I, 15.0 µL of NP1, and 0.50 µL of ALP. For each 50.0 µL of DNA (0.5
mg/mL), calibrators, and quality controls, 4.00 µL of the enzyme cocktail was added and
mixed well. The hydrolysis reaction was carried out for 17 h at 37 ℃.
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4.2.8. Digested products extraction
4.00 µL of IS working solution (20.0 µM) or the mobile phase were added to each
50.0 µL of the digested sample, and vortex-mixed for 30 s; the sample was then
deproteinized with 450 µL of HPLC-grade acetonitrile by vortex mixing for 30 s,
followed by centrifugation at 15000 x g for 10 min. 450 µL of supernatant was pipetted
into a 1.5-mL microcentrifuge tube and evaporated to dryness at 30 ℃ for 60 min in a
TurboVap® LV Evaporator (Zymark, Hopkinton, MA, USA) under a pressurized stream
of nitrogen gas. Finally, each sample was reconstituted in 90.0 µL of deionized water.
For the fludarabine measurement, 5.0 µL of the resulting solution was then injected into
LC-MS/MS for the fludarabine measurement. For the dA measurement, a separate 5.0
µL of the 400 x dilution solution was used.

4.2.9. LC-MS/MS
The liquid chromatography tandem mass spectrometry system was comprised of
an AB Sciex QTRAP 5500 mass spectrometer (Foster City, CA) and a Shimadzu
Prominence UFLC system (Kyoto, Japan) composed of a solvent reservoir, a degasser
(DGU-20A3), a binary pump (LC-20AD), a flow controller (CBM-20A), and an
autosampler (SIL-20ACHT). Data was acquired and analyzed by Analyst software
(version 1.5.1).
The separation of F-ara-A, deoxyribonucleotides, and IS was performed on a
Waters Atlantis® T3 (3 µM, 2.1 mm x 50 mm) column (Waters, Milford, MA, USA) by
gradient elution at ambient at the flow rate of 0.20 mL/min. The eluents used consisted of
mobile phase A (MPA) containing 0.1% formic acid in ultra-pure water and mobile phase
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B (MPB) containing methanol. The program was initiated with 12.5% MPB from 0.0 to
1.0 min, 12.5-50% MPB from 1.0 to 4.0 min, 50-12.5% MPB from 4.0 to 4.1 min, and
12.5% MPB to 5min. The injection volume of each sample was 5 µL. The equilibrate
time between each injection was 5 min.
ESI-MS/MS was operated on the positive-electrospray-ionization (ESI+) mode.
The source-dependent parameters were set as follows: CUR, 30; IS, 5500; TEM, 300;
G1, 40; G2, 40. The compound-dependent parameters were as follows: DP, 50; EP, 50.
Detection of F-ara-A, IS, dA, dG, dC and dT was achieved on MRM with the mass
transition of 286 > 154, 286 > 170, 252 > 136, 268 > 152, 228 > 112 and 243 > 127 m/z,
respectively. The MRM conditions were set as follows: CAD, medium; CE, 30.0; CXP,
13.0; Dewell Time, 100 ms.

4.3.

Results and Discussion

4.3.1. Method development
4.3.1.1. Enzyme digestion optimization
By referring to the work of Yamazoe et al. and Lin et al., a quaternary enzyme
system consisting of DNase I, NP1, PDE I, and ALP was chosen [10, 11]. Among the
four enzymes, DNase I splits phosphodiester bonds preferentially adjacent to pyrimidine
nucleotides and typically yield tetranucleotides [12]. NP1 and PDE I are 5’ to 3’ and 3’
to 5’ exonuclease, respectively. The completely hydrolyzed products of these two
enzymes are dNMPs [13, 14]. When the first three enzymes work together to hydrolyze
the DNA, single strand or double strand, into dNMPs.
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Because the sensitivity of detecting nucleosides by ESI-MS is much higher than
that of detecting nucleotides, the enzymatic cocktail system also contains ALP that can
effectively convert all nucleotides to nucleosides

[14]. To achieve the highest

fludarabine releasing efficiency with the least cost of labor and materials, several
digestion methods were experimented [15].
Comparison between a sequential digestion and the enzyme-cocktail digestion
with the same amount of enzymes for the same total digestion time indicated no
significant difference in the digestion efficiency. Therefore the enzyme-cocktail digestion
was chosen in this project. Furthermore, the best digestion time was experimented. By
digesting DNA with the enzyme cocktail for 5, 10, 15, 20, and 25 h, a kinetic curve was
obtained (data was not shown). From the curve, the optimized digestion time was
between 15 and 20 h. As a result, a total digestion time of 17 h was adopted in this work
due to its best fit to an 8 h working schedule.

4.3.1.2. Mass spectrometric characterization
As seen from Figure 4.2, the expected hydrolysis products from a DNA sample
are F-ara-A along with four deoxyribonucleosides (dG, dA, dC and dT) if the sample is
treated by fludarabine. Thus an LC-MS/MS method has been developed to monitor all of
hydrolysis products.
In this work, full-scan (MS1) and product ion scan (MS2) spectra of F-ara-A,
internal standard (IS) 2-chloro-2′deoxyadenosine and four deoxyribonucleosides (dG, dA,
dC and dT) were acquired. The optimization of the six species responses was done using
the “auto-tune” function of AB Sciex Analyst software (version 1.5.1). Since all of the
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analytes could easily form the protonated species than deprotonated species by
electrospray ionization, the positive electrospray-ionization mode was used for the
identification and quantification. Figure 4.2 displays the typical fragmentation patterns of
the six species and their respective main fragmentation ions.
The spectra showed very similar patterns. Therefore, the mass transition pairs of
m/z 286/154, 286/170, 268/152, 252/136, 228/112 and 243/127 were chosen for the
detection of F-ara-A, IS, dG, dA, dC and dT, respectively, to monitor the LC separation
in MRM.

4.3.1.3. LC separation of enzyme digestion
Figure 4.3A displays LC-MS/MS chromatograms of the 6 molecules with a
loading amount of 1 nmol each. The LC elution conditions were optimized by using 0.1%
formic acid in water and methanol on a Waters Atlantis® T3 (3 µM, 2.1 mm x 50 mm)
column. The final gradient shown in Martials and Methods was selected because it
provided the shortest separation time and the highest separation efficiency. Figure 4.3A
demonstrates complete separation of all 6 molecules within 5 min. Furthermore, the
hydrolysis products from fludarabine treated and untreated cellular DNA sample were
analyzed by LC-MS/MS. IS was added to the sample after hydrolysis for the MRM
analysis. Figure 4.3B displays the result of detecting the products resulted from
hydrolysis of an untreated DNA sample. As expected, dG, dA, dT, dC along with IS were
detected, but F-ara-A was not detected. Figure 4.3C displays LC-MS/MS chromatograms
of hydrolysis products of a DNA sample that was treated by 10 µM fludarabine for 24 h.
As seen from Figure 4.3C, F-ara-A along with dG, dA, dT, dC, and IS, was detected from
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this treated sample, demonstrating that this new method can detect the incorporation of
fludarabine into DNA.

1! 29!

Figure 4.2, Fragmentation spectra of F-ara-A (A); IS (B); dG (C); dA (D); dC (E); and dT
(F).
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Figure 4.3, Representative MRM chromatograms of standard mixture and enzymatic
digested products: (A) the standard mixture of dC, dA, dG, dT, F-ara-A along with IS; (B)
enzymatic digested products from cellular DNA without drug treatment along with IS; (C)
enzymatic digested products from cellular DNA with 10 µM of drug treatment for 24 h
and IS.

1! 31!

4.3.1.4. Using dA as internal standard in sample preparation
Most reported methods have expressed the amount of drugs incorporation into
DNA as pmol of the drug per mg of DNA, wherein the amount of DNA was determined
by UV spectrometer [4, 9]. However, the OD method has limitations that may contribute
to inaccuracy of DNA concentration estimates. For example, DNA quantity can be
misestimated due to contaminations from RNA, protein, lipids, and so forth. Moreover,
DNA is very sticky and the bonding of DNA to pipette tips can dramatically decrease the
accuracy and precision of the experiment. Furthermore, insufficient DNA hydrolysis can
also impair the accurate determination of the incorporated drug. To circumvent these
disadvantages, dA was utilized as the internal standard in sample preparation to cancel
out the experimental errors. We quantified both F-ara-A and dA from the same DNA
sample after hydrolysis reaction and expressed the amount of the drug incorporation as
[F-ara-A]/[dA]. In addition, the DNA quantity also can be calculated based on the
amount of dA by using Eq.1.
[DNA] = [dA] X 617 (g/mol)/ 0.61

(Eq. 1)

Wherein [DNA] is the concentration of DNA in mg/L; [dA] is the measured
concentration of dA in mM; 617 (g/mol) is molar molecular weight of A/T pair; and 0.61
is the percentage of A/T pair in human DNA [16].

4.3.2. LC-MS/MS method validation
4.3.2.1. Calibration curves
Calibration standards for F-ara-A were prepared by serial dilution of F-ara-AMP
working solution. After incubation with the tetra-enzyme cocktail, IS was added to each

1! 32!

sample. The linear calibration ranges (1.00 to 1000 nM) were established by plotting the
peak area ratios of F-ara-A to the IS versus the concentrations of F-ara-A using 1/x2
weighted linear regression (Figure 4.4A). Importantly, linearity and slope of calibration
curve did not change when assessed in calibration standard mixtures of F-ara-AMP and
drug-free DNA (Figure 4.4B). In other words, the similar slope and intercept of the
calibration curves for measuring F-ara-A were obtained in absence or presence of DNA
hydrolysis products and matrix. Although calibrators should ideally be prepared by using
matrix identical to that in the tested samples, our study demonstrated that the presence of
DNA hydrolysis products and matrix did not affect the signal intensity of F-ara-A.
Therefore, to simplify the experimental procedure, we prepared calibrators in solvent
instead of spiking them into DNA hydrolysis matrix. Consequently, the calibration
equation for F-ara-A derived from three validation batches using 1/x2 weighted linear
regression was Y = 0.000479 (±0.000003)X + 4.82e-5 (±1.37e-5) with a coefficient of
determination (r2) of 0.9999. In this work, the lower limit of quantification (LLOQ) was
defined by the lowest calibrators of the calibration curves, which was at 1nM. The
accuracy and precision of each individual calibrator as summarized in Table 4.1, were all
≤ ±13%. These values were well within the FDA guidelines (i.e., ≤ ±15% at all
concentrations except at LLOQ where ≤ ±20%).
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Figure 4.4, Fludarabine calibration curves using (A) fludarabine (1.00-1000 nM) spiked
in buffer; (B) fludarbine (1.00-1000 nM) spiked in drug free DNA sample, (C) dA (10.0400 µM) spiked in buffer; and (D) [5',5''-2H2]2'-dA (10.0-400 µM) spiked in drug free
DNA sample.
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Table 4.1, Calibration equations of F-ara-A (1.00 to 1.00 x103 nM).
Y = 4.79 e-4 (±0.03 e-4) X + 4.82e-5 (±1.37e-5) (r2 = 0.9999 ±0.0000). (n=3)
Nominal [F-ara-A],
nM
1.00
4.00
20.0
40.0
200
400
1.00 x 103

Measured
[F-ara-A],
nM
1.00
4.20
20.5
40.2
207
383
0.95 x 103

SD

Accuracy
(%RE)a

Precision
(%CV)b

0.14
0.33
0.2
1.0
6
18
0.02 x 103

-0.2
5
3
1
4
-4
-5

14
8
1
2
3
5
2

Each datum point was based on three separate measurements in different days.
%RE ={(measured [F-ara-A] − nominal [F-ara-A])/nominal [F-ara-A]} x 100%.
%CV = (standard deviation/mean value) x100%.
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Table 4.2, Intra- and Inter-run accuracy and precision of F-ara-A.
[F-ara-A],
nM
LQC (3.00)
MQC (30.0)
HQC (900)

Intra-run (n=5)a
Accuracy
Precision
(%RE)
(%CV)
1
5
1
5
-8
1

a

Inter-run (n=5)b
! Accuracy
Precision
(%RE)
(%CV)
10
2!
1!
6
5
$5!

Each datum point calculated by five replica measurements of each QCs sample
Each datum point calculated by five parallel measurements of five identical QCs
samples
b
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Table 4.3, Calibration equations of dA (10.0 to 400 µM).
Calibration equations: Y = 1.21 (±0.05)X + 7.58 (±0.72) (r2 = 0.999 ±0.002). (n=3)
Nominal [dA], Measured [dA],
µM
µM
10.0
9.7
20.0
19.9
40.0
44
100
102
200
194
400
372

SD

Accuracy (%RE)

0.3
0.2
3
7
9
8

-3
-1
10
2
-3
-7

Precision
(%CV)
3
1
7
7
5
2

Each datum point was based on three separate measurements in different days.
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Table 4.4, Intra- and Inter-run accuracy and precision of dA.
[dA], µM
LQC (15.0)
MQC (60.0)
HQC (300)

Intra-run
Accuracy Precision
(%RE)
(%CV)
5
2
-3
1
-5
3

!

a

Inter-run
Accuracy
Precision
(%RE)
(%CV)
-5!
3
4!
2
-11!
7

Each datum point calculated by five replica measurements of each QCs sample
Each datum point calculated by five parallel measurements of five identical QCs
samples
b
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Similarly, dA calibration curves were constructed by using six non-zero dA
calibrators along with IS. As described in Section of Experimental, the calibrators were
prepared in BrisTris buffer. The linear calibration ranges (10.0 to 400 µM) were
established by plotting the peak area ratios of dA to the IS versus the concentrations of
dA using 1/x weighted linear regression (Figure 4.4C). The calibration equation was Y =
1.21 (±0.05)X + 7.58 (±0.72) (r2 = 0.999 ±0.002). To assess the interference of DNA
hydrolysis products and matrix, we also built the calibration curve by mixing isotope
standards, [5',5''-2H2]2'-deoxyadenosine ([5',5''-2H2]2'-dA) and drug free DNA with the
same calibration range (10.0 to 400 µM). The presence of DNA hydrolysis products and
matrix did not affect the signal intensity of dA as evidenced by the fact that the slope and
intercept of the calibration curves for dA, which was obtained in solution (Figure 4.4C).
were similar to those for [5',5''-2H2]2'-dA that was obtained in the presence of DNA
hydrolysis matrix. The accuracy and precision of each individual calibrator were given in
Table 4.3, which were well within the FDA guidelines.

4.3.2.2. Accuracy and precision
The inter-run precision and accuracy for F-ara-A were assessed by five parallel
injections from five identical QC samples at low- (3.00 nM), mid- (30.0 nM) and highconcentration (900 nM) lev els (LQC, MQC and HQC). The intra-assay precision and
accuracy were assessed by five replica measurements of each QC samples. As shown in
Table 4.2, the intra-run accuracy expressed as percent relative error (%RE) ranged from 1 to 8%, and the inter-run accuracy values ranged from -5 to 2%. The precision of the
assay expressed as percent standard deviation or coefficient of variation (%CV) varied
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from 1 to 10%.
Similarly, the inter- and intra-run precision and accuracy for dA were summarized
in Table 4. QC samples of dA were at the concentrations of 15.0, 60.0 and 300 µM. As
shown in Table 4.4, the intra- and inter-run accuracy and precision were within ±11%,
indicating that this method is accurate, precise and reproducible.

4.3.3. RNA interference & removal
A potential problem in the measurement of fludarabine incorporated into DNA is
interference from RNA contamination. It is known that F-ara-A can also incorporate into
RNA with a higher rate [17]. We conducted a study to determine the effect of RNA on
measurements of F-ara-A. RNase A is widely utilized to remove RNA in DNA extraction
procedure, however RNase A cleaves only on the 3´ side of pyrimidine residues, yielding
a range of smaller RNAs that may not be fully hydrolyzed, depending on the sequence of
RNA [18]. By contrast, RNase Blend can more effectively hydrolyze RNA [18]. In other
words, RNA would be more fully hydrolyzed when both RNase A and RNase Blend were
used to treat the DNA sample, while some RNAs may not be completely hydrolyzed if
the sample was treated only by RNase A. In this study, treated DNA sample was divided
into two parts. The first part was treated only by RNase A, while the second part was
treated by both RNase A and RNase Blend. Thereafter, all four Ns (products from RNA
hydrolysis), and F-ara-A were detected by LC-MS/MS. As shown in Figure 4.5A, loading
of DNA hydrolysis products from the sample treated by RNase A resulted in all four Ns
peaks observed, indicating RNA contamination. Moreover, an unknown interference peak
was eluted at 5.1 min in F-ara-A MRM channel. By contrast, when the sample was
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treated by both RNase A and RNase Blend, the quantity of Ns was reduced by over 20
folds, indicating that treatment by both RNase A and RNase Blend led to more complete
hydrolysis of RNA (Figure 4.5B). Importantly, the F-ara-A interference peak at 5.1 min
disappeared, indicating that this peak was related to RNA interference. Our study
suggests that after treatment of DNA by both RNase A and RNase Blend, the
contribution of RNA to the measured quantity of F-ara-A is insignificant. In other words,
the F-ara-A molecules detected by this method originated mainly from DNA, not from
RNA. Therefore, in the remaining of this study, all samples were treated with both
RNase A and RNase Blent.
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(B)

Intensity, cps

(A)

Figure
4.5, DNA hydrolysis products from the sample (A) treated by RNase A and (B) both
RNase A and RNase Blend
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4.3.4. Enzyme digestion efficiency
Whether the enzymatic hydrolysis procedure used can fully hydrolyze DNA into
individual nucleosides was tested. As shown in the “Enzyme digestion optimization”
section, when the digestion time was above 15 h, the intensity of digestion products (i.e.,
individual nucleosides) was no longer significantly increased with the incubation time,
indicating that the digestion efficiency has reached the maximum under our condition.
Then, a comparison of the calculated and UV measured DNA quantity was
performed to further validate the digestion efficiency. The rationale for the study is that
the quantity of DNA can be both measured by UV and calculated from the amount of a
nucleoside released from hydrolysis. We used the calibration curve derived above to
determine the amount of dA produced from hydrolysis of 250 mg/L (measured by UV) of
calf DNA. The quantity of dA measured was 0.260 mM. By using Eq. 2, the amount of
DNA to produce 0.260 mM of dA was 267 mg/L if DNA was completely hydrolyzed into
individual nucleosides.
[DNA] = [dA] X 617 (g/mol)/ 0.581

(Eq. 2)

Wherein [DNA] is the concentration of DNA in mg/L; [dA] is the measured
concentration of dA in mM; 617 (g/mol) is molar molecular weight of A/T pair; and
0.581 is the percentage of A/T pair in calf DNA [19]. It was seen that the amount of DNA
calculated (267 mg/L) from the quantity of dA was similar to the amount of DNA
measured by UV (250 mg/L), indicating that the enzymatic hydrolysis procedure used
can essentially completely hydrolyze DNA into individual nucleosides. Importantly, this
result also shows that our new method that combines enzymatic hydrolysis with LC-
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MS/MS can accurately determine the quantity of nucleosides released from DNA
hydrolysis.

4.3.5. Quantification of F-ara-A in fludarabine treated HL-60 & CLL-MEC1
Table 4.5 lists the result of measuring the F-ara-A incorporation into cellular
DNA of the cells cultured under the different drug treatment conditions. In the drug
treatment time study, HL-60 cells were incubated with 10 µM fludarabine for 2 and 24 h,
respectively. An increase in incorporation with the treatment time was observed. The
measured incorporation rate was only 15.9 pmol F-ara-A/mg DNA after 2 h treatment,
but it was 468 pmol/mg DNA after 24 h treatment. In the dosages study, it was seen that
the amount of F-ara-A incorporated into DNA increased with the drug concentration. For
instance, when HL-60 cells were treated by 1 or 10 µM fludarabine for 24 h, the amount
of F-ara-A increased from 306 pmol F-ara-A/mg DNA (1 µM treatment) to 468 pmol Fara-A/mg DNA (10 µM treatment). We also observed the difference in incorporation
among cell lines. For example, after the same treatment, the amount of F-ara-A
incorporated into CLL-MEC1 was 32% less than that into HL-60. This result shows that
this new method can be used to quantitatively measure the incorporation of fludarabine
into DNA of cultured cells, leading to assessment of the efficacy of the drug.

4.4.6. Quantification of F-ara-A in patient’s Lymphocytes
In this study, a patient was recruited and administered with 25 mg/m2 fludarabine
plus 90 mg/m2 methoxyamine. Blood was drawn at 24, 48, 72, 96 and 168 h after
fludarabine dose was given. The results were summarized in Table 4.6. As shown in

1! 44!

Table 4.6, after treated by fludarabine for 24 h, the amount of F-ara-A incorporated into
DNA was 2.5 pmol F-ara-A/mg DNA. After 48 h and 72 h, the amount of F-ara-A
incorporated into DNA was increased to 10.6 and 52.7 pmol F-ara-A/mg DNA. The
highest amount of F-are-A incorporated into DNA was 76.0 pmol F-ara-A/mg DNA
when the patient had been administered with fludarabine after 168 hr. This result shows
that this new method can be used to quantitatively measure the incorporation of
fludarabine into cellular DNA of blood collected from the patient who is treated with
fludarabine.
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Table 4.5, Drug incorporated rates for different cell lines, drug treatment concentrations
and treated times.

Cell line
CLL-MEC1
CLL-MEC1
HL60
HL60
HL60
HL60

Treated
[Fludarabine]
[F-ara-A] [dA]
Time,
nM
treated, µM
µM
Hr
0
10
0
10
1
10

24
24
24
24
24
2

<0
43.9
<0
96.8
75.6
6.24
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152
134
264
201
240
382

Drug
F-ara-A
Incorperated
/DNA,
Rate
(F-ara-A/dA) pmol/mg
N/A
N/A
3.28/10,000
319
N/A
N/A
4.82/10,000
468
3.15/10,000
306
0.16/10,000
15.9

!
!
!
!
!
!
!
!
!
!
!
!
Table 4.6, Drug incorporated rates in patient’s lymphocytes after fludarabine treatment.

Time After
Treatment
Hr
24
48
72
96
168

[F-ara-A] nM

[dA] µM

1.09
2.73
22.8
7.95
33.9

380
255
428
293
441
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Drug Incorperated F-ara-A
Rate
/DNA,
(F-ara-A/dA)
pmol/mg
0.287/10,000
2.8
1.07/10,000
10.6
5.33/10,000
52.7
2.71/10,000
26.8
7.69/10,000
76.0

4.4.

Conclusion
We developed a simple, sensitive, and reliable method for quantifying the

incorporation of fludarabine into cellular DNA, in which the incorporated F-ara-A is first
released from DNA by enzymatic hydrolysis and then quantitated by LC-MS/MS
analysis. This new method can accurately quantify nucleosides and F-ara-A released from
DNA hydrolysis. Moreover, quantitation by this method is highly reproducible. On the
application front, this work demonstrated that this new method could quantitatively
measure the incorporation of fludarabine into DNA of cultured cells, which in turn can be
used to assess the efficacy of the drug. To the best of our knowledge, this is the first nonradioactive assay that can quantitatively measure the incorporation of fludarabine into
cellular DNA. More importantly, we have successfully demonstrated that this new
method can be used to measure the amount of fludarabine incorporated into cellular DNA
of blood collected from the patient who was treated with fludarabine.
Fludarabine can also incorporate into RNA [17]. Although this method is
proposed for measurements of the incorporation of fludarabine into DNA, it can certainly
be used to study the incorporation of fludarabine into RNA as well.
Moreover, Fludarabine is one of many nucleoside analogues that are an important
class of anti-cancer drugs [20]. Although this method is proposed to quantify the
incorporation of fludarabine into cellular nucleic acids, it can be modified to quantify the
incorporation of other nucleoside analogues into cellular nucleic acids.
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4.5.
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CHAPTER V
REVISIT THE CYTOTOXICITY MECHANISM OF FLUDARABINE

5.1.

Introduction
As mentioned in the previous chapter, fludarabine is widely used for the treatment

of chronic lymphocytic leukemia (CLL) [1]. As a single agent, fludarabine has produced
superior response rates and progression-free survival than standard therapy with
chlorambucil and alkylator-based regimen. Although fludarabine is effective in the
treatment of CLL, the response to fludarabine is still limited [2, 3].
The principal action of fludarabine is in the inhibition of DNA synthesis [4] and
incorporating fludarabine (in place of adenosine) into DNA is a major mechanism to
inhibit DNA synthesis. The exact position of fludarabine incorporated into DNA dictates
the mechanism of action. Based on their study that showed the majority of fludarabine
(95%) was incorporated to the terminal position of DNA [5], Plunkett and co-workers
suggested that fludarabine was a DNA extension terminator. In addition, when
fludarabine was incorporated at the 3′-terminus, DNA ligase I would be unable to join it
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to an adjacent piece of DNA [6]. Together, incorporation of fludarabine into the terminal
position could effectively terminate both DNA extension and ligation. Subsequently, the
actions can result in inactivation of DNA synthesis [7-9].
Recent studies by our group suggested that fludarabine also can be incorporated
into the internal position of the DNA chain and activates the base excision repair (BER)
pathway [10]. In that work, we demonstrate that (1) the BER pathway is involved in
processing incorporated fludarabine in DNA through the enzymatic activity of UDG; (2)
MX binding of AP-sites generated directly and indirectly by fludarabine induces unrepairable DNA damage that can block the BER pathway; and (3) MX potentiates the
therapeutic efficacy of fludarabine, allowing for the possibility of a novel therapeutic
strategy to combine inhibitors of BER with fludarabine for clinical treatment. Targeting
BER as a target-based therapeutic strategy can be extended to the combination of MX
with a number of other drugs that incorporate into DNA either by acting as nucleotide
analogs or through the manipulation of the nucleotide pools.
Clearly, an accurate determination of the exact incorporation position of
fludarabine in DNA is essential to elucidating the mechanism of action of fludarabine,
from which one can improve the fludarabine therapeutic efficacy. The traditional method
utilized radioactive isotope-labeled fludarabine to study its incorporation into DNA [5].
In that method, the incorporated DNA was first hydrolyzed, followed by separation and
detection with HPLC-liquid scintillation counting. The drawback of that method is its
inability to directly determine the identity of the products detected and to distinguish two
products with the same retention time. Moreover, that method is not highly accurate
when used for quantification. In this part of our dissertation research, we developed a
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novel LC-MS/MS method in conjunction with enzymatic reactions to quantitatively
determine the amount of the fludarabine incorporated in either the terminal or internal
position in DNA. More importantly, our result suggests that the majority of fludarabine is
incorporated into the internal position of DNA, which is contradictory to the previously
accepted view that fludarabine was mainly incorporated in the 3’-terminal position of
DNA [5]. Reporting this new method and our new result constitute the focus of this
chapter.

5.2.

Experimental

5.2.1 Chemicals and solutions
Formic acid, acetonitrile, ammonium acetate, acetic acid, 2′-deoxyadenosine
(dA), 2′-deoxyadenosine 5′-monophosphate (dAMP), 2′-deoxyguanosine (dG), thymidine
(T),

2′-deoxycytidine

(dC),

2-chloro-2′deoxyadenosine

(2CdA),

thymidine

5′-

monophosphate (TMP) and TE buffer were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Phosphate buffered saline (PBS), N,N-dimethyl hexylamine, water saturated
phenol, optima gradient methanol and chloroform were purchased from Fisher Scientific
(Fair Lawn, NJ, USA). Sodium glycinate, calcium chloride (CaCl2), monopotassium
phosphate (KH2PO4), dipotassium phosphate (K2HPO4), potassium fluoride (KF) and
hydrochloric acid (HCl) were ordered from VWR (West Chester, PA, USA). The 10%
sodium dodecyl sulfate (SDS) was obtained from Bio-Rad Laboratories (Hercules, CA,
USA). RPMI-1640 medium with L-glutamine was purchased from Mediatech (Manassas,
VA, USA). Rnase A and Protease K were ordered from Invitrogen (Carlsbad, CA, USA).
Micrococcal nuclease (MN), phosphodiesterase II (PDE II), bovine alkaline phosphatase
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(ALP), and snake venom phosphodiesterase I (PDE I) were obtained from Worthington
Biochemical Corporation (Lakewood, NJ, USA). Fetal bovine serum was purchased from
Hyclone Laboratories (Logan, UT, USA). Fludarabine (F-ara-AMP) was from Ochem
(Des Plaines, IL, USA). RiboShredder™ RNase Blend was from Epicentre
Biotechnologies (Madison, WI, USA). Deionized water was prepared by a Barnstead
Model 7148 Nanopure® ultrapure water system of the Thermo Scientific (Asheville, NC,
USA).

5.2.2

Cell culture and treatment
Human promyelocytic leukemia cells (HL60) were obtained from American Type

Culture Collection (Rockville, MD, USA). Chronic lymphocytic leukemia (CLL) MEC1
cells were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen
(Braunschweig, Germany). Cells were cultured in RPMI-1640 medium supplemented
with 10% (v/v) fetal bovine serum at 37 ℃ in a humidified 5% CO2 incubator.
F-ara-AMP solutions were freshly prepared for each experiment by dissolving Fara-AMP powder in PBS (1x, pH 7.4). For each 5 × 106 cells, the dosages of F-ara-AMP
added into the culture media were 0.00 or 10.0 µM, respectively. Cells were treated for
24 h at 37 ℃ in a humidified 5% CO2 incubator. After treatment, the cells were removed
from the medium by centrifugation 1500 x g at 4 ℃ for 5 min, and washed with 5 mL
PBS. After centrifugation (1500 x g at 4 ℃ for 5 min), the cell pellets collected were
stored in -20 ℃ till DNA extraction.
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5.2.3

Cellular DNA extraction
2.0 mL of TE buffer (containing 10 mM Tris and 1 mM EDTA at pH 8.0) were

added to the cell pellets. After a short vortex, 240 µL of 10% SDS solution was added
and mixed with the cell suspension gently. The lysates were treated with 20.0 µL of
RNase A (20 mg/mL dissolved in deionized water) at 37 ℃ for 1 h, followed by
treatment with 25.0 µL of protease K (20 mg/mL dissolved in deionized water). After 1 h
incubation at 37 ℃, each sample was transferred to a Phase Lock Gel tube (5 Prime,
Gaithersburg, MD) and centrifuged (4000 x g for 15min) twice with 2.0 mL of phenol,
followed by two times extraction with 2.0 mL of chloroform. After extraction, the
aqueous phase (ca. 2.0 mL) was transferred to a clean 15 mL centrifuge tube and mixed
with 10 mL of pre-chilled ethanol (-20 ℃). The DNA was precipitated at -20 ℃ for
overnight.
After recovering the DNA pellet by removing ethanol through centrifugation
(15000 x g for 15 min), each sample was then washed with 1.0 mL of pre-cooled 70%
ethanol (-20 ℃ ). Thereafter, the samples were air-dried at room temperature and
reconstituted with TE buffer to a final concentration of 1.0 mg/mL (based on UV
absorption at 260 nm). To each 100 µL of DNA sample (1.0 mg/mL), 2.00 µL of
RiboShredder™ RNase Blend (1 U/µL) was added. After 30 min incubation at 37 ℃, the
sample was mixed with 1.0 mL of pre-chilled ethanol (-20 ℃).

The DNA was

precipitated at -20 ℃ for overnight. After centrifugation (15000 x g for 15 min), each
sample was washed with 1.0 mL of pre-cooled 70% ethanol (-20 ℃) twice. Then each
DNA sample was air-dried and reconstituted with 100 µL of deionized water.
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5.2.4

Enzymatic hydrolysis of DNA
Enzymatic hydrolysis was performed with a 3-step reaction by modifying the

procedure described by Manor et al. [11]. Three enzyme solutions were prepared as
following: MN was dissolved in 1 stage buffer solution, which contains 50 mM sodium
glycinate, 2 mM CaCl2, 4 mM TMP, and 0.8 mM TdR at the final concentration of 50
unit/mL; PDE II was dissolved in 2 stage buffer solution, which contains 100 mM
potassium phosphate (pH 6.0), 20 mM TMP, 200 mM ammonium acetate (pH 6.0), 80
mM acetic acid and 50 mM KF at the final concentration of 4 unit/mL; ALP was diluted
in deionized water at the final concentration of 500 unit/mL. For each 50 µL of DNA
sample (1.0 mg/mL), 50 µL of MN solution was firstly added and mixed well. Incubation
was carried out at 37 ℃ for 30 min. The reaction mixture was then cooled in ice, and
followed by adding 10 µL of PDE II solution. After incubation at 37 ℃ for 3 h, sample
was identically divided into two vials. One vial was added with 4 µL of ALP and the
other was added 4 µL of water. The last step hydrolysis was carried out for 2 h at 37 ℃.

5.2.5

Preparation of calibrators and quality controls
The stock standard solutions of F-ara-AMP (4.0 mM), and 2CdA (IS) (2.0 mM)

were prepared in deionized water respectively. The working solution of F-ara-AMP (2.00
µM) and IS (1.00 µM) were prepared by diluting their stock standard solutions with
deionized water individually. The standard working solutions of F-ara-AMP (4.00, 6.00,
8.00, 40.0, 60.0, 80.0, 400, 800, 1800 and 2000 nM) were prepared by serial dilution of
F-ara-AMP working solution (2.00 µM).
The F-ara-A calibrators (2.00, 4.00, 20.0, 40.0, 200, 400 and 1000 nM) and the
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quality controls containing F-ara-A (3.00, 30.0 and 900 nM) were prepared by mixing 25
µL of each F-ara-AMP standard working solution with 25 µL of MN solution, 5 µL of
PDE II solution and 4 µL of ALP. Incubation was carried out at 37 ℃ for 5.5 h.

5.2.6

Digested product extraction
4.00 µL of IS working solution (1.00 µM) was added to each above digested

sample, and vortex-mixed for 30 s; the sample was then deproteinized with 450 µL of
HPLC-grade acetonitrile by vortex mixing for 30 s, followed by centrifugation at 15000 x
g for 10 min. 450 µL of supernatant was pipetted into a 1.5-mL microcentrifuge tube and
evaporated to dryness at 30 ℃ for 60 min in a TurboVap® LV Evaporator (Zymark,
Hopkinton, MA, USA) under a pressurized stream of nitrogen gas. Finally, each sample
was reconstituted in 90.0 µL of deionized water. 5.0 µL of the resulting solution was then
injected into LC-MS/MS for the measurement.

5.2.7

LC-MS/MS
The liquid chromatography tandem mass spectrometry system was comprised of

an AB Sciex QTRAP 5500 mass spectrometer (Foster City, CA) and a Shimadzu
Prominence UFLC system (Kyoto, Japan) composed of a solvent reservoir, a degasser
(DGU-20A3), a binary pump (LC-20AD), a flow controller (CBM-20A), and an
autosampler (SIL-20ACHT). Data was acquired and analyzed by Analyst software
(version 1.5.1). The separation of F-ara-A, and IS was performed on a Waters Atlantis®
T3 (3 µM, 2.1 mm x 50 mm) column (Waters, Milford, MA, USA) by gradient elution at
ambient at the flow rate of 0.20 mL/min. The eluents used consisted of mobile phase A
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(MPA) containing 0.1% formic acid in ultra-pure water and mobile phase B (MPB)
containing methanol. The program was initiated with 12.5% MPB from 0.0 to 1.0 min,
12.5-50% MPB from 1.0 to 4.0 min, 50-12.5% MPB from 4.0 to 4.1 min, and 12.5%
MPB to 5min. The injection volume of each sample was 5 µL. The equilibrate time
between each injection was 5 min. ESI-MS/MS was operated on the positiveelectrospray-ionization (ESI+) mode. The mass spectrometry parameters were set as
follows: CUR, 30; IS, 5500; TEM, 300; G1, 40; G2, 40; DP, 50; EP, 5.0; CAD, medium;
CE, 30.0; CXP, 13.0; and Dewell Time, 100 ms. Detection of F-ara-A and IS was
achieved on MRM with the mass transition of 286 > 154 and 286 > 170 m/z,
respectively.
The measurement of F-ara-AMP was performed on a Waters YMC-AQ® (5 µM,
2.1 mm x 50 mm) column (Waters, Milford, MA, USA) by isocratic elution with 5 mM
N,N-dimethyl hexylamine in water (pH 7.0)/acetonitrile (90/10,v/v) at a flow rate of 0.20
mL/min. The injection volume of each sample was 5 µL. ESI-MS/MS was operated on
the negative-electrospray-ionization (ESI-) mode. The mass spectrometry parameters
were set as follows: CUR, 20; IS, -4500; TEM, 700; G1, 20; G2, 20; DP, -100; EP, -5.0;
CAD, medium; CE, -70; CXP, -14; and Dewell Time, 100 ms. Detection of F-ara-AMP
was achieved on MRM with the mass transition of 364 > 79 m/z.

5.3.

Results and Discussion

5.3.1

Experimental design and enzymatic digestion
In this work, a LC-MS/MS method in conjunction with enzymatic hydrolysis of

DNA was developed to quantitatively determine the amount of fludarabine incorporated
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at the terminal and internal positions in DNA. The enzymes used were MN, PDEII and
ALP.
MN is an endo-exonuclease that can hydrolyze both DNA and RNA. The typical
products by MN digestion are mono- or di-nucleotides with a free 5’-end hydroxyl group
and a free 3’-end phosphate group [12] . PDE II is a 5’ to 3’ exonuclease. The action of
PDE II on DNA requires prior removal of the 5’-end phosphate group and the generation
of a free hydroxyl group. Then it successively hydrolyzes DNA or RNA and releases
single nucleotides with 3’-phosphate [13]. A combination of these two enzymes leads to
the complete hydrolysis of DNA into single nucleotides with 3’-phosphate (from internal
positions) and single nucleosides without phosphate (from terminal positions). In other
words, the product generated from the internal nucleosides would be different from that
produced from the terminal nucleosides. As shown in Figure 5.1, the terminally
incorporated fludarabine is released from the DNA backbone in the form of F-ara-A,
while the internally incorporated fludarabine is released in the form of 3’-F-ara-AMP.
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Figure 5.1, Schematic representation of DNA hydrolysis by 3-step enzymatic digestion including MN, PDE II and ALP

3’

5’

!
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In this study, the F-ara-A molecules released from the terminal position were
directly quantified by the LC-MS/MS method developed in our previous study
(CHAPTER IV). However, for quantification of the 3’-F-ara-AMP molecules released
from the internal position, because there were no 3’-F-ara-AMP molecules commercially
available as standard, we used ALP to further digest the hydrolyzed products produced by
MN/PDE II digestion. ALP is a hydrolase that can effectively remove phosphate from
phosphate-containing molecules. As a result, after digestion by ALP, all the incorporated
fludarabine molecules are converted to F-ara-A regardless of the incorporation positions
and we were able to use LC-MS/MS to quantify the total amount of fludarabine
incorporated after this 3-enzymes hydrolysis reaction. Experimentally, we first divided an
extracted DNA sample into two aliquots. The first aliquot was subject to enzymatic
hydrolysis by only PDE II and MN. After this hydrolysis, we quantified F-ara-A by LCMS/MS, which yielded the amount of fludarabine incorporated in the terminal position.
In contrast, the second aliquot was subject to hydrolysis by MN, PDE II and ALP. After
hydrolysis, we quantified F-ara-A again by using the same LC-MS/MS method, which
corresponded to the total amount of fludarabine incorporated.

5.3.2

Identification and confirmation of the enzymatic hydrolysis products
In this study, cells were first treated by 10 uM fludarabine for 24 h. Cellular DNA

was extracted and divided to two identical parts. The first part was incubated with MN
and PDE II only. After this enzymatic hydrolysis reaction, the hydrolysis products were
identified by MRM. The mass transition pairs of 364/79 and 286/154 were chosen for the
MRM detection of F-ara-AMP and F-ara-A, respectively. As discussed above, after
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hydrolysis by MN and PDE II, the incorporated fludarabine would be released from the
DNA backbone in the form(s) of 3’-F-ara-AMP and F-ara-A. As shown in Spectra A1
and A2 of Figure 5.2, a peak was observed at a retention time of 6.6 min in the F-araAMP mass transition channel (364/79), while another peak was seen at a retention time
of 3.5 min in the F-ara-A mass transition channel (286/154). To confirm that the two
observed peaks corresponded to 3’-F-ara-A and F-ara-A, respectively, several control
studies were performed. In one control study, hydrolysis products from cellular DNA
without drug treatment were studied by LC-MS/MS. As shown in Chromatogram B1 and
B2 of Figure 5.2, no peak was observed in these two mass transitions, indicating that the
peaks shown in Chromatogram A1 and A2 resulted from treatment of DNA by
fludarabine. In addition, we attempted to detect F-ara-AMP and F-ara-A from a treated
DNA sample that was not hydrolyzed. It was seen that without hydrolysis, no peak was
detected (data no shown here), suggesting that the peaks in Chromatogram A1 and A2 of
Figure 5.2 originated from the drug molecules that had been incorporated to cellular
DNA. Furthermore, we incubated pure drug molecules with MN and PDE II. Although
5’-F-ara-AMP and 3’-F-ara-AMP are isomers, it is expected that they would have
different retention times because of difference in their phosphate position. s expected,
fludarabine (5’-F-ara-AMP) was eluted at a retention time of 4.7 min, further suggesting
that the peak at 6.6 min in Chromatogram A1 of Figure 5.2 was not due to the
unincorporated drug molecules. Moreover, there was no peak observed in F-ara-A mass
transition channel, indicating that there is no dephosphorylation occurred under the
experimental condition.
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Figure 5.2, Representative MRM chromatograms of enzymatic-digested products from
drug treated DNA and controls. (A1 & A2): Fludarabine treated HL60 DNA digested by
MN & PDE II; (A3 & A4): Fludarabine treated HL60 DNA digested by MN & PDE II +
ALP; (B1 & B2): No drug treated HL60 DNA digested by MN & PDE II; (B3 & B4): No
drug treated HL60 DNA digested by MN & PDE II + ALP; (C1 & C2): Fludarabine
incubated by MN & PDE II; (C3 & C4): Fludarabine incubated by MN & PDE II + ALP.
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The second part of the DNA sample aliquot was incubated with MN and PDE II
along with ALP, followed by analysis by LC-MS/MS. The result was shown in
Chromatogram A3 and A4 of Figure 5.2 After the 3-enzymes hydrolysis reaction, all of
the incorporated fludarabine molecules are expected to convert to F-ara-A. As expected,
the peak at 6.6 min disappeared in Chromatogram A3 of Figure 5.2, while the peak at 3.5
min increased greatly in Chromatogram A4 of Figure 5.2. In a control study, we also
incubated fludarabine with MN, PDEII and ALP. As shown in Chromatogram C3 and C4
of Figure 5.2, after this 3-enzymes hydrolysis reaction, the peak of 5’-F-ara-AMP was
disappeared, while the peak of F-ara-A was observed at 3.5 min in the mass transition
channel of 266/154, indicating that fludarabine (5’-F-ara-AMP) was successfully
converted to F-ara-A by ALP.
The advantage of LC-MS/MS lies in its high specificity. Moreover, mass
spectrometry can provide the structure information, which, in turn, can be utilized for
identification of unknown molecules. Therefore, to further identify hydrolysis products,
collision-induced dissociation (CID) was utilized to elucidate the fragmentation pattern of
the molecules corresponding to the eluted peaks. Figure 5.3A displays a fragmentation
spectrum of the drug standard (5’-F-ara-AMP), while Figure 5.3B displays the
fragmentation spectrum of the molecules corresponding to the peak at 6.6 min. Highly
similar fragmentation patterns were seen in both Figure 5.3A and B, even though the
retention times of their parent molecules are different. Moreover, the mass positions of
daughter ions were consistent with those of the expected fragments. This fragmentation
study indicated that the molecule corresponding to the peak at 6.6 min shared the same
structural composition of 5’-F-ara-AMP. The difference in the retention time was due to
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the difference in their phosphate position. Similarly, the fragmentation pattern of the
molecule corresponding to the peak at 3.5 min was also acquired (Figure 5.3C), which is
the same as that of the F-ara-A standard (Figure 5.3D). Because the hydrolysis product
molecule corresponding to the peak of 3.5 min has the same retention time, be in the
same mass transition channel, and shares the same fragmentation pattern as the F-ara-A
standard, we believe that this hydrolysis product molecule is F-ara-A.
In summary, our study clearly suggested that the hydrolysis products produced by
MN/PED II digestion were 3’-F-ara-AMP originated from the internally incorporated
fludarabine (Chromatogram A1 in Figure 5.2) and F-ara-A originated from the terminally
incorporated fludarabine (Chromatogram A2 in Figure 5.2), respectively. Moreover, our
study confirmed that the 3-enzymes hydrolysis reaction successfully converted all
incorporated fludarabine into F-ara-A (Chromatogram A4 in Figure 5.2).
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Figure 5.3, Identification of the enzymatic hydrolysis products by MS2 (A)
Chromatogram and fragmentation spectrum of fludarabine (5’-F-ara-AMP) incubated
with MN & PDE II; (B) Chromatogram and fragmentation spectrum of the digested
product (retention time 6.6 min) from a drug treated cell sample incubated with MN &
PDE II; (C) Chromatogram and fragmentation spectrum of fludarabine (5’-F-ara-AMP)
incubated with MN, PDE II and ALP; (D) Chromatogram and fragmentation spectrum of
the digested product from a drug treated cell sample incubated with MN, PDE II and
ALP.
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5.3.3

Quantification of enzymatic hydrolysis products
After identifying hydrolysis products, we utilized the LC-MS/MS method

developed in our previous study (CHAPTER IV) to quantify the amount of F-ara-A
incorporated. The LC separation condition and mass spectrometry parameters were
described in Section 5.2.6. The calibration curve of F-ara-A was developed with seven
non-zero F-ara-A calibrators (1.00, 4.00, 20.0, 40.0, 200, 400 and 1000 nM) along with
IS in each at a fixed concentration (80 nM) (Table 5.1). The calibration equation derived
from three validation batches using 1/x2 weighted linear regression was Y = 0.0107 X +
0.0137 (where Y is the peak area ratio of fludarabine to IS and X is the concentration of
fludarabine) with a coefficient of determination (r2) of 0.999. The method was validated
by three replicate measurements of each QC sample at the concentrations of 3.00, 30.0
and 900 nM. The accuracy and precision of each individual calibrator and QC sample
expressed as the percent relative error (%RE) and coefficient of variation (%CV) were
summarized in Table 5.1, which ranged from -3% to 10%, and 1% to 6%, respectively.
With this new enzymatic hydrolysis method, we also observed an excellent
reproducibility in quantification. This result indicates that the LC-MS/MS method used
can accurately quantify F-ara-A.
As discussed in section 5.3.1, the amount of fludarabine incorporated at the
terminal position and the total amount of incorporated fludarabine can be quantified,
respectively, by using two different hydrolysis approaches, from which the amount of
fludarabine incorporated at the internal position could be deduced. In this study, two
different cell lines CLL-MEC 1 and HL-60 were analyzed. 3 batches of cells for each cell
line were analyzed repeatedly under the same conditions to obtain more accurate results.
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Specifically, each batch of cells was treated with 10 uM of fludarabine for 24 h. After
DNA extraction, each DNA sample was divided to two identical parts. To quantify the
amount of fludarabine at the terminal position, the extracted DNA was incubated with
MN and PDE II only. To quantify the total amount of incorporated fludarabine, the
extracted DNA was incubated with MN and PDE II along with ALP. The results were
summarized in Table 5.2. This study showed that 96.9% of fludarabine was actually
incorporated in the internal position in CLL Mec-1 cellular DNA, while only 3.1% of
fludarabine was incorporated at the terminal position. Similar results were obtained with
HL 60 cells. 97.8% of fludarabine was incorporated at the internal position, while only
2.2% at the terminal position.
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Table 5.1, Calibration equation of F-ara-A (1.00 to 1.00 x103 nM). Calibration equations:
y = 0.0107 x + 0.0137 (r = 0.999).
!
Nominal
[F-ara-A], Measured [F-ara-A], Accuracy
Precision
nM
nM
(%RE)
(%CV)
1.00
0.98
-2
3
4.00
4.16
4
2
20.0
20.1
1
3
40.0
39.3
-2
4
200
199
-1
2
400
410
3
2
3
1.00 x 10
991
-1
1
LQC (3.00)
3.31
10
6
MQC (30.0)
31.2
4
2
HQC (900)
873
-3
2
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Table 5.2, Quantification of fludarabine incorporated at different postions of DNA in
different cell lines.

Cell line

CLLMec1
HL60

[Terminal
incorporate
d drug], nM

[Total
incorporated
drug], nM

2.26
2.81
3.27
3.04
3.31
3.38

61.1
112
109
132
157
154
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F-ara-A
Ratio
(Terminal/
Total) x
100%

F-ara-A
Ratio
(Internal/
Total) x
100%

3.1 ± 0.5 %

96.9 ± 0.5 %

2.2 ± 0.1 %

97.8 ± 0.1 %

We also carried out a control study to determine the accuracy of the method
developed in this study. In this control study, we utilized the same hydrolysis strategy to
quantify the nucleotides (i.e. 2’-deoxyadenosine, 2′-deoxyguanosine, thymidine, and 2′deoxycytidine) released from both the terminal and internal positions of cellular DNA. It
was found that, as expected, the vast majority of these nucleosides were at the internal
position. For example, about 1.4 % of the 2’-deoxyadenosine released from DNA of HL
60 cells were found to be at the terminal position. This control study clearly shown that
this method is highly reliable to quantify the amount of nucleosides incorporated at the
internal and terminal sites, suggesting that the amount of fludarabine incorporated at
different sites of DNA measured by this LC-MS/MS method was accurate.

5.3.4 Detecting the Fludarabine Incorporation in DNA Extracted from Blood
The ultimate application of the method developed in this work is the detection of
the fludarabine incorporation sites in cellular DNA extracted from blood, because this
will allow for the study of the correlation of incorporation with the pain’s response to the
drug at the molecular level. After developing and validating the method, we applied it to
study of the fludarabine incorporation in cellular DNA extracted from the blood of a
patient who had been subjected from the fludarabine treatment, to demonstrate the
feasibility of using this method for clinical application.
Briefly, the blood was drawn at 24 hr after this patient was administrated with
fludarabine. Then our collaborators at University Hospitals extracted raw DNA from the
blood. After receiving the raw DNA, we further purified the DNA and divided an
extracted DNA sample into two aliquots. The first aliquot was subject to enzymatic
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hydrolysis by only PDE II and MN. After this hydrolysis, we quantified F-ara-A by LCMS/MS, which yielded the amount of fludarabine incorporated in the terminal position.
In contrast, the second aliquot was subject to hydrolysis by MN, PDE II and ALP. After
hydrolysis, we quantified F-ara-A again by using the same LC-MS/MS method, which
corresponded to the total amount of fludarabine incorporated. However, in this study, we
didn’t observe any fludarabine from the terminal position, which indicated that the
majority of fludarabine were incorporated into the internal position of patient’s DNA.

5.4.

Conclusion
Fludarabine is an important drug used to treat several cancers, especially chronic

lymphocytic leukemia (CLL). The accurate determination of the incorporation position of
fludarabine in cellular DNA is critically important to a better understanding of the
mechanism of action of this drug, which can in turn allow doctors to develop better
therapeutic strategies. The main discovery of this work is that we found that the vast
majority of fludarabine was actually incorporated in the internal position of DNA. This
result is contradictory to the study of Plunkett et al. [5], in which they found that the
overwhelming majority of fludarabine was incorporated in the terminal position.
As described in the introduction section, Plunkett et al., utilized the similar
MN/PED II enzymatic system to first hydrolyze DNA extracted from the cell lines that
had been treated with the radio-active isotope labeled fludarabine, followed by HPLC
separation and liquid scintillation counting. LC-MS/MS is a “gold-standard” method to
quantify small molecules, particularly drug molecules, because the LC-MS/MS
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quantification is highly accurate and robust. More importantly, an unmatched advantage
of LC-MS/MS over liquid scintillation counting is its capability of identifying the
products produced from enzymatic hydrolysis. In contrast, liquid scintillation counting is
based on detection of molecules containing radio-active isotopes in a given retention time
window. In other words, any molecules containing radio-active isotopes will be
considered as the products if they have retention in the selected detection window.
Although we are not sure that this is the case in the study of Plunkett et al., some of their
own experimental results did suggest that their quantification result was not accurate. In
their control experiment, Plunkett et al. found that ~15% of the incorporated dTMP
appeared at the terminal positions, which suggested that their method greatly over
estimated the amount of dTMP in the terminal position because it is hard to imagine as
many as 15% of dTMP in the terminal position of DNA.
In this work, an LC-MS/MS method in conjunction with enzymatic hydrolysis has
been developed to elucidate the incorporation position of fludarabine in DNA.
Fludarabine is one of many nucleoside analogues that are an important class of anticancer drugs 14 Although this method is developed for fludarabine, it can be modified
to determine the incorporation positions of other nucleoside analogues drugs into DNA.
Fludarabine can also incorporate into RNA [15]. Our preliminary study showed that the
incorporation position of fludarabine in RNA could also be determined using the same
method developed in this work, suggesting that this method could be used to elucidate the
incorporation sites of nucleoside analogous drugs in RNA as well.
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CHAPTER 6
REVISIT THE INCORPORATION OF 9-β-D-ARABINOFURANOSYL-2FLUOROADENINE (FLUDARABINE) INTO RNA
!
!
6.1.

Introduction
As described in Chapters 4 and 5, fludarabine, an adenosine analogue, is widely

used for the treatment of hematological malignancies including chronic lymphocytic
leukemia (CLL), acute myeloid leukemia (AML), and non-Hodgkins lymphomas [1-3].
The principal action of fludarabine is in the inhibition of nucleic acid synthesis [4]. In
addition to the incorporation into DNA, fludarabine can also incorporate into RNA [5-7].
In fact, the ability to incorporate into RNA is one of the properties of fludarabine that
differ from those of ara-A.
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Plunkett et al. was the first to study the action of fludarabine on RNA metabolism
[8]. In that study, they utilized the same method [9] involving the radioactive isotopelabeled fludarabine to study the fludarabine incorporation. With that method, they were
able to quantify the amount of fludarabine incorporated into RNA. They found that
fludarabine was preferentially incorporated into the (poly)A+ RNA fraction over the
(ploy)A- RNA fraction. In the same study, they also found that approximately 78% of the
incorporated fludarabine were located at the terminal position of the RNA chain. Based
on this evidence, they suggested that the incorporation of fludarabine into mRNA (as an
RNA synthesis terminator) resulted in premature termination of the RNA transcript and
impaired its functioning as a template of protein synthesis.
As pointed out above, the method that Plunkett et al. utilized for their RNA study
was also based on HPLC-liquid scintillation counting in conjunction with enzymatic
digestion of nucleic acids. As described in Chapter 5, the drawback of that method is its
inability to directly determine the identity of the products detected and to distinguish two
products with the same retention time. In other words, any molecules that contain radioactive isotopes and have the retention time in the detection window would be considered
as the target products. Moreover, that method is not highly accurate when used for
quantification. Therefore, in the study of Chapters 4 and 5, we developed a LC-MS/MS
method in conjunction with enzymatic hydrolysis to study the incorporation of
fludarabine into DNA. We found that some of our results generated by using our LCMS/MS method were different from those resulted from the study of Plunkett et al. For
example, we found that the overwhelming majority of fludarabine was incorporated into
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the internal positions of the DNA chain, while Plunkett et al. suggested that it was mainly
incorporated into the terminal position.
Considering the drawbacks of the conventional method, which led to the different
conclusion on the incorporation of fludarabine into DNA, we decided to revisit the
incorporation of fludarabine into RNA by using the same LC-MS/MS method developed
in the study of Chapters 4 and 5. With this new method, we were able successfully to
determine the total quantity of fludarabine incorporated into RNA. In addition, we were
able to elucidate the primary incorporation position of fludarabine in RNA in cultured
cells. Unlike Plunkett et al.’s result, our study suggested that the majority of the
fludarabine incorporated was in the middle position. Reporting the results arising from
the use of our LC-MS/MS based method to study the incorporation of fludarabine into
RNA constitutes the focus of this chapter.

6.2.

Experiment

6.2.1.

Materials

Formic acid, acetonitrile, ammonium acetate, acetic acid, adenosine (A), guanosine (G),
thymidine (T), cytidine (C), 2-chloro-2′deoxyadenosine (2CdA), thymidine 5′monophosphate (TMP) and TE buffer were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Phosphate buffered saline (PBS), N,N-dimethyl hexylamine, water saturated
phenol, optima gradient methanol and chloroform were purchased from Fisher Scientific
(Fair Lawn, NJ, USA). Sodium glycinate, calcium chloride (CaCl2), monopotassium
phosphate (KH2PO4), dipotassium phosphate (K2HPO4), potassium fluoride (KF) and
hydrochloric acid (HCl) were ordered from VWR (West Chester, PA, USA). The 10%
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sodium dodecyl sulfate (SDS) was obtained from Bio-Rad Laboratories (Hercules, CA,
USA). RPMI-1640 medium with L-glutamine was purchased from Mediatech (Manassas,
VA, USA). Micrococcal nuclease (MN), phosphodiesterase II (PDE II), bovine alkaline
phosphatase (ALP), and snake venom phosphodiesterase I (PDE I) were obtained from
Worthington Biochemical Corporation (Lakewood, NJ, USA). Fetal bovine serum was
purchased from Hyclone Laboratories (Logan, UT, USA). Fludarabine (F-ara-AMP) was
from Ochem (Des Plaines, IL, USA). TRIzol® Reagent was obtained from Life
technologies (Grand Island, NY, USA). Deionized water was prepared by a Barnstead
Model 7148 Nanopure® ultrapure water system of the Thermo Scientific (Asheville, NC,
USA).

6.2.2. Cell Culture
Human promyelocytic leukemia cells (HL60) were obtained from American Type
Culture Collection (Rockville, MD, USA). Cells were cultured in RPMI-1640 medium
supplemented with 10% (v/v) fetal bovine serum at 37 ℃ in a humidified 5% CO2
incubator.
F-ara-AMP solutions were freshly prepared for each experiment by dissolving Fara-AMP powder in PBS (1x, pH 7.4). For each 5 × 106 cells, the dosages of F-ara-AMP
added into the culture media were 0.00 or 10.0 µM, respectively. Cells were treated for
24 h at 37 ℃ in a humidified 5% CO2 incubator. After treatment, the cells were removed
from the medium by centrifugation 1500 x g at 4 ℃ for 5 min, and washed with 5 mL
PBS. After centrifugation (1500 x g at 4 ℃ for 5 min), the cell pellets collected were
stored in -20 ℃ till RNA extraction.
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6.2.3.

RNA Extraction
1.00 mL of TRIzol® Reagent was added to the cell pellets. Lyse cells in sample

by pipetting up and down several times. After incubating for 5 min at room temperature,
0.2 mL of chloroform was added to the sample. After shaking vigorously by hand for 15
seconds, the sample was incubated at room temperature for 2-3 min, followed by
centrifugation at 12.000 x g for 15 min at 4 ℃. The mixture separated into a lower red
phenol- chloroform phase, an interphase, and a colorless upper aqueous phase. The
aqueous phase contained RNA was removed and placed into a new tube. RNA was
isolated by adding 0.5 mL of 100% isopropanol. After incubation at room temperature for
10 min, the sample was centrifuged at 12000 x g for 10 min at 4 ℃. The RNA pellet was
collected and washed with 1 mL of 75% ethanol. Then each RNA sample was air-dried
and resuspended in RNase free water at 1.00 mg/mL.

6.2.4.

Remove DNA contamination
To each 50 µL of RNA sample (1.0 mg/mL), 5.00 µL of 10X Baseline-ZERO

DNase Reaction Buffer and 2.5 μl of Baseline-ZERO DNase were added. After 30 min
incubation at 37 ℃, the sample was mixed with 1.0 mL of pre-chilled ethanol (-20 ℃).
The DNA was precipitated at -20 ℃ for overnight. After centrifugation (15000 x g for 15
min), each sample was washed with 1.0 mL of pre-cooled 70% ethanol (-20 ℃) twice.
Then each DNA sample was air-dried and reconstituted with 50 µL of deionized water.
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6.2.5.

Enzymatic Hydrolysis of RNA
Enzymatic hydrolysis was performed with a 3 step reaction by modifying the

procedure described by Manor et al [10]. Three enzyme solutions were prepared as
following: MN was dissolved in 1 stage buffer solution, which contains 50 mM sodium
glycinate, 2 mM CaCl2, 4 mM TMP, and 0.8 mM TdR at the final concentration of 50
unit/mL; PDE II was dissolved in 2 stage buffer solution, which contains 100 mM
potassium phosphate (pH 6.0), 20 mM TMP, 200 mM ammonium acetate (pH 6.0), 80
mM acetic acid and 50 mM KF at the final concentration of 4 unit/mL; ALP was diluted
in deionized water at the final concentration of 500 unit/mL. For each 50 µL of RNA
sample (1.0 mg/mL), 50 µL of MN solution was firstly added and mixed well. Incubation
was carried out at 37 ℃ for 30 min. The reaction mixture was then cooled in ice, and
followed by adding 10 µL of PDE II solution. After incubation at 37 ℃ for 3 h, sample
was identically divided into two vials. One vial was added with 4 µL of ALP and the
other was added 4 µL of water. The last step hydrolysis was carried out for 2 h at 37 ℃.

6.2.6.

Preparation of Calibrators and Quality Controls
The stock standard solutions of F-ara-AMP (4.0 mM), 2CdA (IS) (2.0 mM), and

AMP (4.0 mM) were prepared in deionized water respectively. The working solutions of
F-ara-AMP (2.00 µM) and AMP (2.00 mM) were prepared by diluting their stock
standard solutions with deionized water individually. The standard working solutions of
F-ara-AMP (0.80, 2.00, 4.00, 8.00, 40.0, 80.0, 120 and 200 nM) were prepared by serial
dilution of F-ara-AMP working solution (2.00 µM). The standard working solutions of
AMP (200, 400, 600, 800, 1200 and 2000 µM) were prepared by serial dilution of dAMP
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working solution (2.00 mM).
The F-ara-A calibrators (0.40, 1.00, 2.00, 4.00, 20.0, 40.0, 60.0 and 100 nM) were
prepared by mixing 25 µL of each F-ara-AMP standard working solution with 25 µL of
MN solution, 5 µL of PDE II solution and 4 µL of ALP.
The AMP calibrators (100, 200, 300, 400, 600 and 1000 µM) were prepared by
mixing 25 µL of each dAMP standard working solution with 25 µL of MN solution, 5 µL
of PDE II solution and 4 µL of ALP.
!
6.2.7.

Digested Product Extraction
4.00 µL of IS working solution (1.00 µM) was added to each above digested

sample, and vortex-mixed for 30 s; the sample was then deproteinized with 450 µL of
HPLC-grade acetonitrile by vortex mixing for 30 s, followed by centrifugation at 15000 x
g for 10 min. 450 µL of supernatant was pipetted into a 1.5-mL microcentrifuge tube and
evaporated to dryness at 30 ℃ for 60 min in a TurboVap® LV Evaporator (Zymark,
Hopkinton, MA, USA) under a pressurized stream of nitrogen gas. Finally, each sample
was reconstituted in 90.0 µL of deionized water. For the fludarabine measurement, 5 µL
of the resulting solution was then injected into LC-MS/MS for the fludarabine
measurement. For the adenosine (A) measurement, a separate 5 µL of the 400 x dilution
solution was used.

6.2.8.

LC-MS/MS
The liquid chromatography tandem mass spectrometry system was comprised of

an AB Sciex QTRAP 5500 mass spectrometer (Foster City, CA) and a Shimadzu
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Prominence UFLC system (Kyoto, Japan) composed of a solvent reservoir, a degasser
(DGU-20A3), a binary pump (LC-20AD), a flow controller (CBM-20A), and an
autosampler (SIL-20ACHT). Data was acquired and analyzed by Analyst software
(version 1.5.1). The separation of F-ara-A, and IS was performed on a Waters Atlantis®
T3 (3 µM, 2.1 mm x 50 mm) column (Waters, Milford, MA, USA) by gradient elution at
ambient at the flow rate of 0.20 mL/min. The eluents used consisted of mobile phase A
(MPA) containing 0.1% formic acid in ultra-pure water and mobile phase B (MPB)
containing methanol. The program was initiated with 12.5% MPB from 0.0 to 1.0 min,
12.5-50% MPB from 1.0 to 4.0 min, 50-12.5% MPB from 4.0 to 4.1 min, and 12.5%
MPB to 5min. The injection volume of each sample was 5 µL. The equilibrate time
between each injection was 5 min. ESI-MS/MS was operated on the positiveelectrospray-ionization (ESI+) mode. The mass spectrometry parameters were set as
follows: CUR, 30; IS, 5500; TEM, 300; G1, 40; G2, 40; DP, 50; EP, 5.0; CAD, medium;
CE, 30.0; CXP, 13.0; and Dewell Time, 100 ms. Detection of F-ara-A, IS, A, G, C, U and
dT was achieved on MRM with the mass transition of 286 > 154, 286 > 170, 268 > 136,
284 > 152, 244 > 112, 245 > 113, and 243 > 127 m/z respectively.

6.3.

Results

6.3.1.

Experimental Design and Enzymatic Digestion
In this work, an LC/MS/MS method in conjunction with enzymatic hydrolysis of

RNA was developed to quantitatively determine the total amount of fludarabine
incorporated into RNA as well as the amount of fludarabine incorporated at both the
terminal and internal positions in RNA. The enzymes used were MN, PDEII and ALP,
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which were the same to those described in Chapter 5. The enzymatic system can
hydrolyze both DNA and RNA. A combination of MN and PDEII leads to the complete
hydrolysis of RNA into single nucleotides with 3’-phosphate (from internal positions)
and single nucleosides without phosphate (from terminal positions). In other words, the
product generated from the internal nucleosides would be different from that produced
from the terminal nucleosides. A combination of MN, PDE II and ALP leads to the
complete hydrolysis of RNA into single nucleosides without phosphate. In other words,
all the incorporated fludarabine molecules are converted to F-ara-A regardless of the
incorporation positions. We used LC-MS/MS to quantify the total amount of fludarabine
incorporated after this 3-enzymes hydrolysis reaction.
The similar experimental procedure described in Chapter 5 was used in this study.
Briefly, we first divided an extracted RNA sample into two aliquots. The first aliquot was
subject to enzymatic hydrolysis by only PDE II and MN. After this hydrolysis, we
quantified F-ara-A by LC-MS/MS, which was the amount of fludarabine incorporated in
the terminal position of RNA. In contrast, the second aliquot was subject to hydrolysis by
MN, PDE II and ALP. After hydrolysis, we quantified F-ara-A again by using the same
LC-MS/MS method, which yielded the total amount of fludarabine incorporated.

6.3.2.

Determination of the Enzymatic Hydrolysis Products
Since the 3-enzyme digestion can hydrolyze an RNA sample into A, G, U and C

along with F-ara-A, we first established the separation and detection conditions for
monitoring all digestion products. In this work, we used 2-Chloro-2′deoxyadenosine
(2CdA) as internal standard (IS) for quantification of F-ara-A, and dT as IS for
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quantification of A. By using the LC-MS/MS condition described in Section 6.2.8, all 7
molecules were well separated and detected. Fig, 6.1 shown the results of hydrolysis of
an RNA sample that was treated by 10 µM fludarabine for 24 h. dT was added to the
enzyme buffer system. 2CdA was spiked into the sample after hydrolysis by the 3enzyme system. As expected, F-ara-A along with G, A, U, C, dT and 2CdA, was detected
from this treated sample, demonstrating that our enzyme system could digest RNA well
and the expected digestion products could be well separated and detected. We also
conducted a control experiment to ensure that the F-ara-A molecules detected resulted
from hydrolysis of RNA, not from the residual fludarabine used to treat cells. In this
quality control experiment, we attempted to detect F-ara-A from a treated RNA sample
that was not hydrolyzed. It was seen that without hydrolysis, no F-ara-A was detected
(data no shown here), suggesting that the F-ara-A molecules detected was originated
from the F-ara-A molecules that had been incorporated to cellular RNA.
Next, we further studied hydrolysis by either the 2-enzyme or 3-enzyme systems.
In this study, HL60 cells were first collected. RNA was extracted and divided to two
identical parts. The first part was incubated with MN and PDE II only. As discussed
above, after hydrolysis by MN and PDE II, fludarabine incorporated at the terminal site
was released in the form of F-ara-A. In other words, the F-ara-A molecules detected from
hydrolysis of RNA by MN and PDEII was those incorporated at the terminal position.
The second part of the RNA sample aliquoted was first incubated with MN and PDE II
along with ALP, followed by analysis by LC-MS/MS. After the 3-enzymes hydrolysis
reaction, all of the incorporated fludarabine molecules were expected to convert to F-araA. Therefore, the amount of the F-ara-A molecules detected from hydrolysis of RNA by
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MN, PDEII and ALP corresponded to the total amount of fludarabine incorporated into
RNA.
As shown in Spectra of Fig. 6.2A1 and A2, when we studied RNA collected from
the cells that were not treated by drug, as expected, no F-ara-A was observed. Next, we
studied RNA collected from the cells treated with 10 µM fludarabine for 5 or 24 h. For
the 5hr treatment sample, F-ara-A (Fig. 6.2B2) was detected when RNA was hydrolyzed
by the three enzymes system, but not observed with the two enzymes system (Fig.
6.1B1). For the 10 hr treatment sample, F-ara-A was detected with both enzyme systems
(Figs. 6.2C1 and C2). Clearly, those results demonstrated that (1) the fludarabine
incorporated into RNA could be released by our enzyme systems and detected by our LCMS/MS method; 2) the fludarabine incorporated at the different positions can be
distinguished by using two different enzymatic systems.
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Figure 6.1. Representative MRM chromatograms of enzymatic digested products from
cellular RNA with 10 µM of drug treatment for 24 h and IS by MN & PDE II + ALP.
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Figure 6.2. Representative chromatograms of enzymatic-digested products from drug
treated RNA and controls. (A1): No drug treated HL60 RNA digested by MN & PDE II
Fludarabine; (A2): No drug treated HL60 RNA digested by MN & PDE II + ALP; (B1) 5
hr treated HL60 RNA digested by MN & PDE II; (B2): 5 hr treated HL60 RNA digested
by MN & PDE II + ALP; (C1): 24 hr treated HL60 RNA digested by MN & PDE II;
(C2): 24 hr treated HL60 RNA digested by MN & PDE II + ALP.
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6.3.3. Quantification of enzymatic hydrolysis products
In this study, we utilized the LC-MS/MS method developed in the study of
Chapters 4 and 5 to quantify the amount of F-ara-A incorporated. The calibration curve
of F-ara-A was developed with seven non-zero F-ara-A calibrators (0.40, 1.00, 2.00, 4.00,
20.0, 40.0, 60.0 and 100 nM) along with IS in each at a fixed concentration (100 nM)
(Fig 6.3A). The calibration equation derived from three validation batches using 1/x2
weighted linear regression was Y = 0.00771 X + 0.0137 (where Y is the peak area ratio
of fludarabine to IS and X is the concentration of fludarabine) with a coefficient of
determination (r2) of 0.997.
As discussed above, the amount of fludarabine incorporated at the terminal
position and the total amount of incorporated fludarabine can be quantified, respectively,
by using two different hydrolysis approaches, from which the amount of fludarabine
incorporated at the internal position could also be deduced. In this study, 3 batches of HL
60 cell line were analyzed repeatedly under the same conditions to obtain more accurate
results. Each batch of cells was treated with 10 uM of fludarabine for 24 h. After RNA
extraction, each RNA sample was divided to two identical parts. To quantify the amount
of fludarabine at the terminal position, the extracted RNA was incubated with MN and
PDE II only. To quantify the total amount of incorporated fludarabine, the extracted RNA
was incubated with MN and PDE II along with ALP. This study showed that 96.7% of
fludarabine was incorporated in the internal position in cellular RNA extracted from
HL60, while only 3.3% of fludarabine was incorporated at the terminal position.
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A!

B!

Figure 6.3, Calibration curves (A) F-ara-A (0.4 -100 nM) and (B) Adenosine
(100 -1000 uM).
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In this study, we also studied the drug incorporation rate, which was expressed as
the ratio of [F-ara-A]/[A]. Therefore, we quantified both total F-ara-A and A from the
same RNA sample after hydrolysis of RNA by the 3-enzyme system. A calibration curves
were constructed by using six non-zero A calibrators (100, 200, 300, 400, 600 and 1000
µM ) along with dT. The calibration equation derived from three validation batches using
1/x2 weighted linear regression was Y = 0.0042X + 0.0675 (where Y is the peak area
ratio of A to dT and X is the concentration of A) with a coefficient of determination (r2)
of 0.9994.
HL60 cells were treated with 10 µM fludarabine for 5 and 24 hr, respectively. The
results were summarized in Table 6.1. The measured incorporation rate expressed as the
ratio of [F-ara-A]/[A] ratio was 0.43/10,000 after 5 h treatment, while it was 1.45/10,000
after 24 h treatment. For comparison, we also measured the amount of F-ara-A
incorporated into DNA from the same cell samples. The DNA incorporated rate
expressed as the ratio of [F-ara-A]/[dA] was 0.44/10,000 after 5 h treatment, and
4.70/10,000 after 24 h treatment.
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Table!6.1,!The!rate!of!fludarabine!incorporated!into!both!RNA!and!DNA!
Drug
Drug
F-ara-A
F-ara-A
Sample
Incorperated
[Fludarabine] Treated Incorperated /RNA,
/DNA,
Type
Rate
Rate
treated, µM Time,
(HL60)
(F-ara-A/A) pmol/mg (F-ara-A/dA) pmol/mg
RNA
10
5
N/A
N/A
0.43/10,000
37
RNA
10
24
1.45/10,000
N/A
N/A
109
DNA
10
5
N/A
N/A
0.44/10,000
41.4
DNA
10
24
N/A
N/A
4.70/10,000
445

!
!
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6.3.4. DNA interference and removal
Since fludarabine can incorporate into both DNA and RNA, a potential problem
associated with measurements of fludarabine incorporated into RNA is interference from
the DNA contamination. After extracting RNA from cell lyses by TRIzol® Reagent, we
hydrolyzed the RNA samples by MN, PDEII and ALP. Deoxyribonucleosides including
dA, dC, and dG were observed in hydrolysis products, indicating the presence of the
DNA contamination. To solve this problem, Baseline-ZERO DNase was added to our
RNA sample. In this study, extracted RNA was divided into two parts. The first part was
not subject to further treatment, while the second part was treated by Baseline-ZERO
DNase. As shown in Table 6.2, when the RNA sample was treated with Baseline-ZERO
DNase, the quantity of dNs was reduced by over 20 folds, indicating that treatment by
Baseline-ZERO DNase led to effectively remove the DNA contamination. Moreover,
after removing the DNA contamination, the amount of F-ara-A was reduced by about 3
folds, indicating that without the Baseline-ZERO DNase treatment, the amount of F-araA measured was due to incorporation to both DNA and RNA. This study also suggested
that after treatment of RNA by Baseline-ZERO DNase, the contribution of DNA to the
quantity of F-ara-A measured was insignificant. In other words, with the Baseline-ZERO
DNase treatment, the F-ara-A molecules detected by this method originated mainly from
RNA, not from DNA. Therefore, in the remaining of the study of this chapter, all
samples were treated with Baseline-ZERO DNase.
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Table 6.2, Comparison of Treatment with and without Baseline-ZERO DNase.
dG
Sample

dA

dC

F-ara-A

Rel. Int. (%)

Rel. Int. (%)

Rel. Int. (%)

100

100

100

100

4.8

5.3

4.3

20.6

Rel. Int.
(%)

Without
DNase
With DNAse
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6.4.

Conclusion
In this work, an LC-MS/MS method in conjunction with enzymatic hydrolysis has

been utilized to elucidate the incorporation position of fludarabine in RNA. Fludarabine
is an important drug used to treat several cancers, especially chronic lymphocytic
leukemia (CLL). The accurate determination of the incorporation position of fludarabine
in cellular RNA is also critically important to a better understanding of the mechanism of
action of this drug, which can in turn allow doctors to develop better therapeutic
strategies. The main discovery of this work is that we found that the vast majority of
fludarabine was actually incorporated in the internal position of RNA. This result is
contradictory to the study of Plunkett et al. [8], in which they found that the majority of
fludarabine was incorporated in the terminal position.
As described in Chapter 5, Plunkett et al., utilized the similar MN/PED II
enzymatic system to first hydrolyze nucleic acids extracted from the cell lines that had
been treated with the radio-active isotope labeled fludarabine, followed by HPLC
separation and liquid scintillation counting. An unmatched advantage of LC-MS/MS over
liquid scintillation counting is its capability of identifying the products produced from
enzymatic hydrolysis. In contrast, liquid scintillation counting is based on detection of
molecules containing radio-active isotopes in a given retention time window. In other
words, any molecules containing radio-active isotopes will be considered as the products
if they have retention in the selected detection window. As discussed in Chapter 5, the
inability of their method to identify hydrolysis products may be a potential source of
overestimating the amount of fludarabine incorporated in the terminal position by
Plunkett et al. Fludarabine is one of many nucleoside analogues that are an important
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class of anti-cancer drugs 14 Although this method is developed for fludarabine, it can
be modified to determine the incorporation positions of other nucleoside analogues drugs
into RNA.
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